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Abstract 
 
Staphylococcus aureus is one of the most important human pathogens, being a major 
cause of infections worldwide both in the hospital and in the community. 
In Portugal, the prevalence of methicillin resistant S. aureus (MRSA) in hospitals is one 
of the highest in Europe and has been characterized extensively; contrarily the 
prevalence and epidemiology of MRSA in the community has not been followed in a 
meaningful way. 
To understand the epidemiological events that could explain a steep increase in MRSA 
frequency in a major Portuguese central hospital (HSM) within a 17 year period, two 
MRSA collections recovered in 1993 (n=54) and 2010 (n=180) from pus, blood and 
urine were analyzed by PFGE, MLST, spa and SCCmec typing. The results showed that 
a major clonal shift occurred, wherein ST22-IVh clone has replaced the previous 
ST239-IIIvar and ST247-I clones and accounts for more than 70% of the present 
population. Moreover, an increase in genetic diversity of MRSA clonal types was 
observed between the two study periods. 
With the aim of determining the frequency and clonal nature of MRSA and methicillin-
susceptible S. aureus (MSSA) causing skin and soft tissue infections (SSTI) in patients 
attending healthcare centers in Portugal, 73 samples were collected from nine healthcare 
centers (Medicos Sentinela Network). A total of 40 S. aureus were isolated, accounting 
for 55% of the SSTI, of which 17.5% were MRSA. MRSA isolates belonged to ST22-
IVh (n=4), ST5-IVc (n=2) and ST105-II (n=1) that have also been described in the 
hospital in an equivalent period. 
Our results suggest that the increase in MRSA frequency in HSM may be associated to 
the emergence of a MRSA clone with higher epidemic potential. Moreover, we propose 
that the spillover of MRSA from the hospital rather than community-associated-MRSA 
was the main cause of SSTI in persons attending healthcare centers in Portugal. 
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Resumo 
 
Staphylococcus aureus é um dos principais agentes patogénicos humanos, sendo 
frequentemente associado a infecções nosocomiais e infecções na comunidade. 
A prevalência de S. aureus resistentes à meticilina (MRSA) em hospitais portugueses é 
uma das mais elevadas da Europa e tem sido caracterizada extensivamente; 
contrariamente, a prevalência e epidemiologia de MRSA na comunidade em Portugal 
não tem sido devidamente seguida.  
Com o objectivo de compreender as causas possíveis do aumento na frequência de 
MRSA num dos maiores hospitais centrais portugueses (HSM) ao longo de 17 anos, 
isolados de MRSA recolhidos em 1993 (n=54) e 2010 (n=180) de pus, sangue e urina 
foram analisados por PFGE, MLST, tipagem do spa e tipagem de SCCmec. Os 
resultados mostraram que ocorreu uma mudança global nos tipos clonais 
predominantes, onde o clone ST22-IVh substituiu os clones, ST239-IIIvar e ST247-I, 
representando mais de 70% da população actual. Além disso, entre 1993 e 2010 
verificou-se um aumento na diversidade genética dos tipos clonais de MRSA. 
Para determinar a frequência e a natureza clonal de MRSA e S. aureus sensíveis à 
meticilina (MSSA) isolados de infecções de pele e tecidos moles (SSTI) em pessoas que 
frequentam centros de saúde em Portugal, 73 amostras foram recolhidas em nove 
centros de saúde (Rede Médicos Sentinela). Isolou-se um total de 40 S. aureus (55%), 
dos quais 17,5% eram MRSA. Os isolados de MRSA pertenciam aos clones ST22-IVh 
(n=4), ST5-IVc (n=2) e ST105-II (n=1), que foram descritos neste estudo como sendo 
clones de origem hospitalar. 
Os nossos resultados sugerem que o aumento da frequência de MRSA no HSM pode 
estar associado à emergência de um clone de MRSA com maior capacidade epidémica. 
Além disso, verificámos que a principal causa de SSTI em pessoas que frequentam 
centros de saúde em Portugal são MRSA de origem hospitalar e não MRSA associados 
à comunidade. 
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Chapter 1. Introduction 
 
1.1 Staphylococcus aureus – Historical Perspective 
 
Staphylococcus aureus is the most important pathogen in the Staphylococcus genus. It 
was first described in 1880, by Louis Pasteur and Alexander Ogston, as small spherical 
bacteria causing pus from furuncles and abscesses, having been called micrococci. 
However, Ogston was the first to demonstrate that these bacteria produced 
inflammation and suppuration and introduced the name Staphylococcus derived from 
the Greek staphyle (from bunch of grapes). In 1884, Rosenbach provided the first 
taxonomic description of the genus Staphylococcus based on the colonies’ 
pigmentation, dividing the genus in two species, Staphylococcus aureus (aureus from 
the Latin word for gold) and Staphylococcus albus (albus from the Latin word for 
white), later renamed Staphylococcus epidermidis (94). 
 
1.2 The Staphylococcus genus 
 
The genus Staphylococcus comprises more than 40 species and several subspecies 
(http://www.bacterio.cict.fr/s/staphylococcus.html), all of them sharing some common 
characteristics. Morphologically they are gram-positive cocci of approximately 0.5-1.5 
m of diameter, dividing in three perpendicular planes to form grape-like clusters. 
These bacteria have a distinct cell wall composed of teichoic acids and a peptidoglycan 
characterized by several layers of N-acetylglucosamine and N-acetylmuramic acid 
linked by a -(1,4)-glycosidic bond and cross-linked by five glycine residues in the 
interpeptide bridge, in the case of S. aureus, which renders them susceptible to 
lysostaphin (112). 
Staphylococci are nonmotile, nonflagelate, facultative anaerobes, glucose fermenting, 
catalase-positive and usually oxidase-negative. They are also characterized by their 
tolerance to high concentrations of NaCl, with the majority being able to grow in the 
presence of 1.7 M of NaCl. Staphylococci are among the hardiest non-spore forming 
bacteria, resisting to drying and to heat (as high as 60ºC for 30 min). Staphylococci are 
also characterized by having a low G+C content (30-38%) (135, 200). 
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1.3 The Staphylococcus aureus species 
 
Staphylococcus aureus is characterized by its capacity to produce the coagulase enzyme 
or clumping factor, which is a cell surface-associated fibrinogen-binding protein that, in 
the presence of human plasma, causes agglutination. This property is useful for 
distinguishing S. aureus from other staphylococci that are unable to produce coagulase 
and that are referred to as coagulase-negative staphylococci (CoNS) (135). Also, S. 
aureus is capable of fermenting mannitol aerobica- and anaerobically. When grown on 
mannitol salt agar, a yellow zone is formed around the colony due to the fermentation of 
mannitol and production of acid. Additionally, S. aureus can also metabolize glucose, 
xylose, lactose, sucrose, maltose and glycerol. 
In complex media, S. aureus is able to grow within a wide range of pH (4.8-9.4) and 
temperature (10º to 45ºC), showing a minimal doubling time of 30 to 40 min (135). 
 
1.4 Staphylococcus aureus colonization and pathogenicity 
 
S. aureus is a commensal organism that is frequently found colonizing the skin and 
mucosas of mammals but can also be found in birds. In humans, its primary niche for 
colonization are the anterior nares although it can be found colonizing other parts of the 
body such as the pharynx, hands, forearms, gastrointestinal tract, perineum, vagina and 
axillae, but in a lower frequency (193, 198). 
Overall, three patterns of nasal carriage can be distinguished: ~20% (range 12-30%) of 
people are persistent carriers, ~60% (range 16-70%) are transiently carriers and another 
20% (range 16-69%) are non-carriers of S. aureus (95). The pattern of nasal carriage 
seems to depend on a complex interplay between bacterial factors and host 
characteristics (53, 187). Importantly, some studies show that persistent carriers are at a 
higher risk of developing infection than non-carriers (134, 149, 199). Transmission of S. 
aureus can be accomplished by direct contact (e.g., skin-to-skin contact with an infected 
or colonized person), by indirect contact (e.g., contact with a contaminated surface or 
object) or by airborne transmission (193). 
Some groups within the general population seem to be at a higher risk for S. aureus 
colonization, presenting increased S. aureus carriage rates. In these groups are included: 
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hospitalized patients, healthcare workers, patients with diabetes mellitus (both insulin 
dependent and non-insulin dependent), patients undergoing haemodialysis or 
continuous peritoneal dialysis, HIV patients, patients with viral infections of the upper 
respiratory tract, patients with S. aureus skin infections and skin disease (e.g., eczema 
or psoriasis), obesity, history of cerebrovascular accidents and intravenous drug users. 
More recently, veterinary staff, pet owners and (pig) farmers have also been considered 
at risk for S. aureus colonization (110, 181, 190, 198). 
 
Because S. aureus is capable of causing infection when the skin and mucous 
membranes become disrupted, it is also considered an opportunistic pathogen. Infection 
caused by S. aureus can range from mild conditions, such as skin and soft tissues 
infections (e.g., cellulitis, folicullitis, mastitis, impetigo, furuncles, superficial and deep 
skin abscesses, wound infections), to severe life-threatening diseases (e.g., pneumonia, 
meningitis, bacteremia, endocarditis, osteomyelitis) and toxin-mediated diseases (e.g., 
toxic shock syndrome, scalded skin syndrome and food poisoning) (112, 181). 
 
1.5 Antibiotic resistance in Staphylococcus aureus 
 
Prior to the antibiotic era, the mortality rate of S. aureus invasive infections was 
extremely high, exceeding 80% (171). However, in the early 1940s, with the 
introduction of the first ß-lactam antibiotic named penicillin, the patients’ prognosis 
improved considerably. Unfortunately, shortly after the introduction of penicillin into 
medical practice, the first resistant isolates soon emerged. This resistance was 
associated to the production of a plasmid-encoded ß-lactamase enzyme (1). Since then, 
resistance to penicillin has been progressively increasing. Nowadays, more than 90% of 
staphylococcal isolates produce ß-lactamases (111). 
Soon after the introduction of penicillin, other antimicrobial agents were developed and 
used to treat S. aureus infections, including chloramphenicol, erythromycin, 
streptomycin and tetracycline. Nevertheless, resistance to these antimicrobials rapidly 
emerged, often mediated by plasmids and transposons (107).  
In the beginning of the 1960s new drugs emerged like the first cephalosporins, 
gentamicin and more importantly, the first semi-synthetic ß-lactamase resistant 
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penicillin, called methicillin (and later also oxacillin). However, within two years of the 
introduction of methicillin in clinical use, the first methicillin-resistant S. aureus 
(MRSA) were reported (86). Since then, multidrug-resistant MRSA became a major 
health problem in hospital, frequently accumulating and developing resistance to every 
class of antimicrobials and spreading worldwide (45). Currently, due to the multiple 
resistance often presented by healthcare-associated MRSA (HA-MRSA) in hospitals, 
therapeutic choices are limited. Glycopeptides, namely vancomycin, is one of the few 
antibiotics effective against these microorganisms, being considered a last resort 
antibiotic. Nevertheless, in 1996, the first vancomycin-intermediate S. aureus (VISA) 
strain was reported in Japan (80) followed in 2002, by the first vancomycin-resistant S. 
aureus strains reported in the USA (28). Importantly, in 2008 the first VISA strain from 
a Portuguese hospital was also reported (64). 
While HA-MRSA became one of the major pathogens in the nosocomial setting, in the 
mid 1990s MRSA began to cause infections in the community in previously healthy 
people (27, 186). However, these MRSA strains, designated as community-associated 
MRSA (CA-MRSA) were distinct from HA-MRSA, having a different genetic 
background and being frequently susceptible to non- -lactams classes of antimicrobials 
(41).  
Alternative drugs have been developed to treat MRSA infections (108), however these 
are generally expensive (e.g., quinupristin-dalfopristin, tigecycline, daptomycin and 
linezolid) or reveal a high level of toxicity to the patients (e.g., rifampicin), and 
resistance to these antimicrobials has already been observed. Therefore, the 
development of new antimicrobial agents and, more importantly, new measures to 
prevent infections and to control the spread of MRSA are warranted.  
 
1.5.1 ß-lactam antibiotics and mechanisms of resistance  
 
The ß-lactams are a broad class of antibiotics, which the primary target are the PBPs 
(penicillin-binding proteins) that are involved in the final stages of peptidoglycan 
synthesis. The PBPs (1 to 4) are responsible for the transglycosylation and/or 
transpeptidation reactions. ß-lactam antibiotics bind to the native PBPs present in the 
wall of susceptible S. aureus, inactivating their transpeptidase domain. By this way, the 
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final stages of the cross-linking in the peptidoglycan are inhibited, consequently leading 
to bacterial death (17). 
In S. aureus, resistance to ß-lactam antibiotics can occur mainly by two mechanisms. 
One mechanism, conferring resistance only to penicillin, is based on the production of 
the ß-lactamase enzyme encoded by the blaZ gene, which cleaves the beta-lactam ring 
of penicillin, rendering it ineffective (116). Another broader resistance mechanism 
conferring resistance to most ß-lactams is based on the acquisition of an exogenous 
resistance determinant, the mecA gene (78). Due to its clinical and epidemiological 
importance, this mechanism will be further described. 
Other mechanisms of resistance to ß-lactams were also described, including the 
hyperproduction of ß-lactamase enzyme (116) and the alteration of the native PBPs by 
mutation (183). 
 
1.5.2 Methicillin resistance: the mecA gene and the staphylococcal cassette 
chromosome mec (SCCmec) element 
 
The central element conferring resistance to methicillin and all other ß-lactam 
antibiotics is the mecA gene (2.1kb in length), which encodes for a penicillin-binding 
protein, PBP2a or PBP2’, with low affinity to all ß-lactam antibiotics (78). In the 
presence of ß-lactam antibiotics the transpeptidase domain of the four S. aureus native 
PBPs is inactivated but the transpeptidase domain of PBP2a remains active, which 
together with the transglycosilase of the native PBP2, ensures the synthesis of 
peptidoglycan (153). 
The mecA gene is carried in a mobile genetic element named staphylococcal cassette 
chromosome mec (SCCmec) that integrates at the 3’ end of orfX, an open-reading frame 
(ORF) with unknown function located in the S. aureus chromosome near the origin of 
replication (82, 89). SCCmec is composed by: (i) the mec gene complex containing 
mecA and its regulators; (ii) the ccr gene complex containing site-specific recombinases 
- cassette chromosome recombinases (ccr) and (iii) the presence of flanking direct and 
inverted repeats (85). 
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According to the International Working Group on the Classification of Staphylococcal 
Cassette Chromosome Elements (IWG-SCC), the SCCmec elements are defined by the 
combination of the class of the mec gene complex and the ccr gene complex.  
So far, five major classes of mec gene complex were described in S. aureus: mec 
complex A, B, C (C1 and C2) and E (see Table 1) (85). An additional mec complex 
class, class D, was described in coagulase-negative staphylococci (CoNS) (88) but so 
far was not found in S. aureus. 
 
Table 1 – Structure of mec gene complex classes currently described and associated SCCmec types. 
Adapted from (http://www.sccmec.org) 
mec gene complex Structure SCCmec types 
class A IS431-mecA-mecR1-mecI II, III, VIII 
class B IS431-mecA-ΔmecR1-IS1272 I, IV, VI 
class C1 IS431-mecA-ΔmecR1-IS431 (two IS431s are 
arranged in the same direction) 
VII, X 
class C2 IS431-mecA-ΔmecR1-IS431 (two IS431s are 
arranged in the opposite direction) 
V, IX 
class D IS431-mecA-ΔmecR1 * 
class E blaZ-mecALGA251-mecR1LGA251-mecILGA251 XI 
* No SCCmec was attributed. 
 
The ccr gene complex is composed by the ccr genes and surrounding open reading 
frames, several of which have unknown functions. The ccr genes encode for 
recombinases belonging to the invertase/resolvase family and are responsible for the 
excision/integration of SCCmec from/into the chromosome (85, 89). Currently, three 
phylogenetically distinct ccr genes ( 50% of nucleotide identities) have been described: 
ccrA, ccrB and ccrC, where ccrA and ccrB can be further differentiated in allotypes 
(nucleotide identities between 60% and 82%). 
Two structures of ccr complex can be identified: one carrying two adjacent genes, ccrA 
and ccrB, and the other carrying only one gene, ccrC. Eight ccr gene complex types 
were already described (see Table 2): types 1 to 4, carrying two genes, ccrA and ccrB 
with four allotypes: ccrAB1, ccrAB2, ccrAB3, ccrAB4; type 5 carrying a single allotype, 
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ccrC1; type 7 carrying the combination of ccrA1B6 and type 8 carrying the combination 
ccrA1B3 (http://www.sccmec.org). Additionally, ccr type 6 (ccrA5B6) was found in a 
CoNS isolate strain but not in S. aureus (208). 
 
Table 2 – Structure of ccr gene complex types and associated SCCmec types currently described. 
Adapted from (http://www.sccmec.org) 
ccr gene complexes Structure (allotypes) SCCmec types 
Type 1 A1B1 I, IX 
Type 2 A2B2 II, IV 
Type 3 A3B3 III 
Type 4 A4B4 VI, VIII 
Type 5 C1 V, VII 
Type 6 A5B3 * 
Type 7 A1B6 X 
Type 8 A1B3 XI 
*No SCCmec was attributed. 
 
Up until now, eleven SCCmec types were identified in S. aureus: SCCmec type I (class 
B mec complex, ccrA1B1), SCCmec type II (class A mec complex, ccrA2B2), SCCmec 
type III (class A mec complex, ccrA3B3), SCCmec type IV (class B mec complex, 
ccrA2B2), SCCmec type V (class C2 mec complex, ccrC1), SCCmec type VI (class B 
mec complex, ccrA4B4), SCCmec type VII (class C1 mec complex, ccrC1), SCCmec 
type VIII (class A mec complex, ccrA4B4), SCCmec type IX (class C2 mec complex, 
ccrA1B1), SCCmec type X (class C1 mec complex, ccrA1B6) and SCCmec type XI 
(class E mec complex, ccrA1B3) (18, 63, 81-83, 85, 102, 113, 142, 205).  
In addition to mec and ccr gene complexes, the SCCmec element also contains three 
joining regions (J1, J2 and J3) (previously named “junkyard regions”), which are 
nonessential components of the cassette that may carry pseudogenes or additional 
antimicrobial resistance determinants encoded in mobile genetic elements such as 
insertion sequences, transposons and plasmids (85). 
The J1 region is located between the right chromosomal junction and the ccr complex; 
the J2 region is located between the ccr gene complexes and the mec gene complex; and 
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the J3 region is between the mec complex and the left chromosomal junction. Overall, 
SCCmec structure can be summarized as containing a J1-ccr-J2-mec-J3 structure, where 
the variations and polymorphisms within the same combination of mec and ccr 
complexes are used to define SCCmec subtypes (85, 121). 
In the last years SCCmec type IV has raised particular interest. SCCmec type IV is the 
smallest structural type of SCCmec and believed to be the most mobile version. It has 
been found among community-associated MRSA strains (CA-MRSA) (204) and is 
characteristic of some important nosocomial MRSA clones, such as the EMRSA-15 
clone, which is endemic in the UK (87) and is spreading in many other countries (8, 9, 
120), including Portugal (4, 11, 43). So far, ten SCCmec type IV subtypes (IVa through 
IVl) have been described, based in the variations of J1 region only (19, 84, 121). 
 
Currently, the definition of MRSA clone is based on the SCCmec type carried by the 
isolate and its clonal background (sequence type - ST) defined by multilocus sequence 
typing (MLST), as proposed by Enright el al. (55). 
 
1.6 Virulence factors and their role in pathogenesis in S. aureus 
 
S. aureus has a wide variety of virulence factors that play an important role in the 
establishment of infection and pathogenesis. 
These virulence factors may be involved in different stages of infection and can be 
grouped into: (i) attachment and adherence to host tissues (e.g., clumping factors, 
fibronectin-binding proteins); (ii) tissue invasion/penetration (proteases, lipases, 
nucleases, hyaluronate lyase and metalloproteases) (iii) evasion and destruction of host 
defenses [cytolysins (e.g. phenol-soluble modulins (PSMs), capsular polysaccharides, 
protein A, chemotaxis inhibitory protein (CHIPS)] and (iv) persistence in the host (e.g., 
biofilm accumulation) (69). 
S. aureus is also able to produce a myriad of toxins such as: enterotoxins (SEA to SEQ) 
responsible for food poisoning, superantigenic toxins [e.g., toxic shock super toxin-1 
(TSST-1)], responsible for toxic shock syndrome, and epidermolysins or exfoliative 
toxins (ETA, ETB, ETC and ETD) the major causes of bullous impetigo and 
staphylococcal scalded skin syndrome (SSSS) (69). 
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1.6.1 Panton Valentine Leukocidin – PVL 
 
More recently, staphylococcal cytolysins, namely Panton-Valentine leukocidin (PVL) 
have been demonstrated as key determinants of S. aureus infections. 
Panton Valentine Leukocidin (PVL) is a S. aureus two-component pore forming protein 
that belongs to the family of synergohymenotropic toxins. PVL was first described by 
Van deVelde in 1894, although Panton and Valentine were the first to associate it with 
skin and soft tissue infections (SSTI) in 1932 (41).  
PVL is encoded by the lukPV operon, comprising the co-transcribed lukF-PV and lukS-
PV genes, and carried by several temperate bacteriophages (21, 207). Being a 
leukocidin, PVL has the ability of forming pores in the membranes of human 
polymorphonuclear neutrophils (PMNs), monocytes, and macrophages, consequently 
leading to their lysis or apoptosis, in a concentration-depending manner (23, 147).  
PVL has been strongly associated with CA-MRSA infections in several epidemiological 
studies, being considered one of the molecular markers for CA-MRSA. Although strong 
and unequivocal epidemiological correlation between the presence of PVL and the 
severity of disease exist, still the increased virulence potential of PVL-positive MRSA 
strains has been difficult to prove due to discordant results obtained for different animal 
and infection models (23, 49, 101, 104, 195). So far, PVL was already found associated 
with several different clones (STs) and genetic backgrounds (CC) such as CC5, CC8, 
CC15, C22, CC30, CC59, ST45, ST72, CC80, CC88, ST93, ST154, ST398 and ST772 
(127). 
 
1.6.2 Arginine catabolic mobile element – ACME 
 
ACME is a 30.9 kb DNA chromosomal encoded element that has been hypothesized to 
play a role in the pathogenesis of MRSA, especially CA-MRSA, by enhancing its 
ability to colonize the skin of healthy people and, in that way, to disseminate in the 
community (50). ACME comprises two main gene clusters, the arc genes and opp3 
operon, and three allotypes have been described so far in staphylococci. ACME type I, 
which has been strongly associated with ST8-IV strains (USA300 clone) (47), contains 
the two gene clusters, arc and opp3, whereas ACME type II only contains the arc 
cluster and ACME type III only contains the opp3 cluster. The ACME types I, II and 
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III, as well as some variants of these allotypes, were described in S. epidermidis (14, 
125). 
 The arcA gene encodes an arginine deiminase that inhibits nitric oxide production, a 
metabolite produced by human macrophages and other leukocytes in response to 
bacterial infections. Also, it seems to play a role in ATP production and in survival at 
low pH (4.2-5.9), which is the pH usually found in the skin and in the intracellular 
milieu. The opp3 cluster encodes a putative oligopeptide permease operon (opp) that 
belongs to the ABC transporter family, which can be associated to a wide array of 
functions, including peptide nutrient uptake, quorum sensing, pheromone transport, 
chemotaxis, eukaryotic cell adhesion, binding of serum components and expression of 
virulence determinants (47, 48, 147). However, the real contribution of this element to 
the virulence of CA-MRSA has still to be clearly demonstrated. A study by Diep et al. 
(50) showed that USA300 had a superior fitness compared to its isogenic mutant with 
ACME and SCCmec deleted, suggesting that ACME may be advantageous. In contrast, 
a study by Montgomery et al. (130) did not show any difference in virulence between 
USA300 strains and its isogenic ACME knock-out mutant in a rat model of necrotizing 
pneumonia or skin infections. Therefore, the role of ACME in USA300 pathogenesis 
remains controversial. 
ACME integrates into orfX and is flanked by repeat sequences characteristic of SCCmec 
elements but does not contain ccr. Its mobilization is believed to be achieved by the 
recombinases encoded by SCCmec, namely the ccrAB2 complex present in SCCmec 
type IV that is normally found in tandem with ACME in S. aureus (50). 
ACME has been found in different clonal backgrounds, other than ST8-IVa, such as 
ST5-II (50, 66), ST59-IVa (50), ST97-V (51), ST1-IVa (51), ST5-IV (52), ST239-III 
(65), also two ST8 MSSA isolates (66) and in some species of coagulase-negative 
staphylococci, where it seems to be more prevalent (14, 125, 152). More recently, a 
novel type of ACME was described in ST22-IV (169) that has significant homology to 
ACME II found in Staphylococcus epidermidis, which reinforces the hypothesis that 
ACME might have been acquired through horizontal transfer and recombination events 
occurring between CoNS and S. aureus (47, 169). 
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1.7 Typing of Staphylococcus aureus 
 
S. aureus is one of the most important human pathogens in the hospital setting with an 
increasing importance in the community as well. Therefore, the efficient monitoring and 
control of this pathogen is crucial, which requires efficient typing tools. In order to 
better understand the epidemiology and the molecular evolution of this pathogen, 
several typing techniques have been developed throughout the years, each one 
providing a characterization of the pathogen at different levels in terms of evolutionary 
time clock and discrimination power, and targeting different loci, according to the 
purpose of the study. 
 
1.7.1 PFGE 
 
Pulsed-field gel electrophoresis (PFGE) is one of the most discriminatory typing 
methods for S. aureus, having been considered for a long time the gold standard method 
to investigate MRSA nosocomial outbreaks and also to describe the local and 
worldwide dissemination of S. aureus clones (37, 44).  
PFGE was first described in 1984 to analyze chromosomal DNA of eukaryotic 
organisms (165) and afterwards has proven to be applicable to several other organisms, 
namely bacteria, including S. aureus (106). 
PFGE involves the embedding of the bacterial cells in agarose, their lysis in situ and the 
digestion of the bacterial total DNA with a low frequency cutting restriction 
endonuclease, generating a small number of DNA fragments. These DNA fragments are 
resolved in a special electrophoretic apparatus, in which the electric field is applied in 
pulses that vary in time and orientation according to a predetermined pattern, producing 
a macro restriction pattern of distinct bands (12). 
For the interpretation of the macro restriction patterns obtained by PFGE, consensus 
guidelines allow drawing conclusions on epidemiological relatedness based on the 
comparison of PFGE macro restriction profiles. According to these S. aureus 
established guidelines, for an outbreak situation an isolate is considered to be closely 
related to the outbreak strain if its restriction pattern differs from the outbreak pattern by 
changes consistent with a single genetic event, i.e., a point mutation or an insertion or 
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deletion of DNA, resulting in two to three band differences; possibly related to the 
outbreak strain if restriction pattern differs from the outbreak pattern by changes 
consistent with two independent genetic events (i.e., four to six band differences); and 
unrelated to the outbreak strain if its PFGE pattern differs from the outbreak pattern by 
changes consistent with three or more independent genetic events (generally seven or 
more band differences) (115, 180). However, nowadays the analysis of the macro 
restriction patterns is usually assisted by bioinformatics tools, such as Bionumerics 
software (v6.1 Applied Maths, Saint- Martens-Latem, Belgium) where a set of 
guidelines (e.g., image acquisition, internal controls, data range for analysis) are taken 
into account so that the method of analysis can be standardized and applicable intra and 
inter-laboratory (26, 58).  
PFGE has been considered a highly discriminatory and reproducible technique with a 
high typeability. However is a time-consuming and laborious technique. Moreover, the 
interlaboratory comparison and standardization are difficult to achieve (176), although 
several attempts have been made in order to harmonize the procedures and improve data 
interchangeability (32, 37, 131, 189) 
 
1.7.2 spa typing 
 
Currently, a widely used technique is spa typing that was initially described by Frenay 
et al. (62). This technique is based on the sequencing of the polymorphic X region or 
short sequence repeat (SSR) of S. aureus protein A gene (spa), a surface protein 
anchored in the cell membrane of most S. aureus that has the ability to bind selectively 
to the fragment crystallizable (Fc) region of immunoglobulin G (IgG), leaving the 
antigen-combining sites free, in this way preventing opsonization (69). This 
polymorphic X region consists of a variable number of small repeats, usually of 24bp 
(although 21, 27 and 30bp repeats were already described) (http://spaserver.ridom.de) 
and is located immediately upstream of the region encoding the C-terminal cell wall 
attachment sequence. Even though the X region presents a high diversity due to point 
mutations, deletions and duplications of the repetitive units, its flanking regions are well 
conserved allowing the annealing of primers and the direct amplification and 
sequencing of this region (167). 
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To the sequence of each different repeat an alphanumerical code is attributed and to the 
combination of these repeats a specific spa type is assigned (76). Two different 
nomenclature systems used for spa typing were developed (76, 97). The one more 
widely used uses the Ridom software for automatic analysis and type attribution (Ridom 
GmbH, Wurzburg, Germany); it has proven to be a valuable tool, for the comparison of 
spa typing data using a uniform nomenclature while providing an excellent quality 
control of the data (2). All spa data is synchronized to an online database, the SpaServer 
(http://spaserver2.ridom.de/index.shtml), for the assignment of the spa repeats and spa 
types. The European SeqNet network (http://www.seqnet.org) is responsible for the 
curation of the SpaServer database, being one of the largest databases for S. aureus 
typing. 
Overall, spa typing has a high reproducibility, typeability and a good discriminatory 
power [between that of PFGE and multilocus sequence typing (see below)] (176) and 
one of its greatest advantages is the easy data exchangeability (2). 
Because of its capacity to cover genetic variations that accumulate both rapidly and 
slowly changes (micro- and macro-variation), spa typing is considered a valuable tool 
for outbreaks, local and global epidemiology, and population-based studies (97). It has 
also the advantages of being less expensive, less laborious and time consuming and easy 
to perform, as compared to MLST and PFGE, since involves sequencing of a single 
locus (168, 174). Furthermore, the implementation of the algorithm based upon repeat 
pattern (BURP) (118), in association with StaphType, allowed the establishment of 
phylogenetic relatedness using spa typing data, enabling the clustering of spa types into 
clonal lineages with a good concordance with other typing methods such as MLST (CC) 
and PFGE types (37, 58, 75, 97, 174, 175).  
 
1.7.3 Multilocus sequence typing - MLST 
 
MLST was first described in 1998 (114) for the characterization of Neisseria 
meningitidis lineages and was afterwards adapted to other microorganisms including S. 
aureus (56). MLST is a molecular typing technique based on the nucleotide sequencing 
of an internal region of seven housekeeping genes. For S. aureus, the genes analyzed by 
MLST scheme are the following: carbamate kinase (arcC), shikimate dehydrogenase 
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(aroE), glycerol kinase (glp), guanylate kinase (gmk), phosphate acetyltransferase (pta), 
triosephosphate isomerase (tpi), and acetyl coenzyme A acetyltransferase (yqiL) (54).  
For each gene sequence a distinct allele is assigned; the combination of the seven alleles 
defines an allelic profile to which a sequence type (ST) is attributed. The ST assignment 
(e.g., ST22, allelic profile: 7-6-1-5-8-8-6) is performed through an open access database 
on the Internet (www.mlst.net), in which the sequences obtained from isolates all over 
the world can be deposited and compared. 
To analyze and compare MLST data an algorithm named BURST or eBURST (from 
electronic based upon related sequence types) was developed (59). This tool is freely 
available on the Internet (http://eburst.mlst.net) and allows the determination of the 
pattern of descendance among a particular population (55, 59).  
The algorithm eBURST is based on the theory that a genotype within a population, 
whether by a fitness advantage or random genetic drift, eventually can become 
predominant and then gradually starts diversifying (by mutation or recombination) to 
produce variants that differ in only one or more of the seven loci that are called single-, 
double- or triple-locus variants (SLV, DLV and TLV). In this way, a cluster of STs in 
an eBURST diagram in which all STs are linked as SLVs to at least one other ST is 
defined as clonal complex (CC) and the founder of each CC, is defined as the most 
predominant ST and the one with the largest number of SLVs. Moreover, large clonal 
complexes typically contain subgroups and therefore have both primary and subgroup 
founders, where an SLV of the primary founder may have increased in frequency and 
diversified to generate a number of its own SLVs, thus becoming a subgroup founder 
(59). In the case of S. aureus, a CC was defined as a cluster of isolates that share at least 
five identical alleles (42). 
The eBURST analysis can be represented graphically (see Figure 1), where each ST is 
represented as a circle and the frequency of each ST (i.e., the number of isolates of the 
ST in the input data) is indicated by the area of the circle. SLVs are connected to the 
primary founder of the group by a solid line. The primary group founder is represented 
in blue and the subgroup founder is represented in yellow (59).  
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MLST has the big advantage of being suitable for long-term epidemiological studies, 
since it is based on variations in housekeeping genes that evolve slowly, allowing for an 
overall view of the long-term evolution and population biology of S. aureus. Because 
the data obtained from MLST analysis is based on DNA sequences it is unambiguous 
and can be easily interchanged. On the other hand, MLST has the disadvantages of 
being expensive, laborious and time consuming (44, 176). 
 
1.7.4 SCCmec typing 
 
Due to the high diversity in SCCmec organization and genetic content, several typing 
methods have been described over the years to determine the structure of this genetic 
element. The determination of the SCCmec type is epidemiologically and clinically 
relevant, since the currently accepted definition of MRSA clones is based on the 
combination of SCCmec type with clonal background (ST) (55). 
Most of the methods described in the last years are PCR-based methods that, either by 
conventional PCR or multiplex PCR, rely on the amplification of different loci within 
the several types of the cassette. Basically, there are two main approaches for SCCmec 
type discrimination: one that is based on the individual determination of mec complex 
and ccr complex (31, 81, 83, 139), and the other that is based on the determination of 
the structural differences in J regions of each SCCmec type (22, 96, 122, 141, 206). In 
2006, two studies described a new approach for the inference of the SCCmec type I to 
IV and VI, based on the sequencing of an internal fragment of the ccrB locus using a 
Figure 1 – eBURST diagram representing the S. aureus clonal complex (CC) 22. Accessed 
on January 5, 2012. 
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pair of degenerated primers (103, 143). The sequences can then be submitted and 
analyzed in an online database (www.ccrbtyping.net), where a ccrB allele is assigned. 
ccrB showed to have a good correlation with SCCmec types and could be used as a 
first-line assay or simply as a confirmation tool of the SCCmec type assignment (144). 
Additionally, due to the increasing number of MRSA infections in the community, the 
typing and subtyping of SCCmec type IV became important. A typing scheme was 
proposed by Milheiriço et al., based on the detection of variations within the J1 region, 
enabling the identification of SCCmec types IVa to IVh (121). 
In parallel to PCR-based methods, real-time PCR strategies have also been described for 
SCCmec typing. These methods have the advantages of requiring a short time and less 
labor in the PCR preparation and to have a fast and easy to interpret output. Still, real-
time PCR is expensive, as it requires special equipments and reagents (185). 
Recently, rules were established for the nomenclature, description and identification of 
SCCmec and other SCC elements in order to avoid the ambiguities and inconsistencies 
in the published literature (85). 
The continuous emergence of new SCCmec types, like the recently described SCCmec 
types IX, X and XI (63, 102), is a challenging issue for the typing strategies since the 
description of a new SCCmec type easily leads to obsolete schemes. 
 
1.8 Molecular epidemiology of S. aureus 
 
Shortly after the introduction of methicillin into clinical use to treat infections caused by 
penicillin-resistant S. aureus, the first MRSA strain was reported from UK in 1961 (86). 
In the following years, MRSA strains disseminated to several other European countries. 
However was only in the mid 1980s that MRSA became pandemic, having spread 
worldwide and accumulated resistance to almost all antimicrobial classes (45, 111). 
During this time, MRSA infections seemed to be confined mainly to hospitals and other 
healthcare facilities. However, in the mid-late 1990s MRSA started to emerge in the 
community (27, 186) and have been increasing ever since in different parts of the world. 
These MRSA were genetically different from those usually found in the hospitals and 
also in the kind of infections they caused and the populations affected (60, 132). 
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However, nowadays these community-associated MRSA can also be identified as a 
cause of hospital-onset and health-care associated infections, suggesting that certain 
clones have the ability to cross barriers between hospitals and the community (93, 146). 
Worryingly, MRSA strains that were thought to be restricted to animals are being 
increasingly seen also in humans, as causative agents of infection (40, 201, 202).  
 
1.8.1 Origin and evolution of Hospital-associated MRSA (HA-MRSA) 
 
Healthcare associated MRSA are among the most common causes of bacteremia, 
surgical site infections, pneumonia, and urinary tract infections in the nosocomial 
setting, as are also commonly associated with prosthetic-device and catheter-related 
infections (181). Common risk factors for HA-MRSA infections include prolonged 
hospitalization or residency at a nursing home, undergoing dialysis, use of indwelling 
catheters, Intensive Care Unit exposure, prior antimicrobial therapy or surgical 
procedures, and close proximity to a inpatient colonized with MRSA (30). Frequently, 
HA-MRSA are multidrug-resistant and carry the larger SCCmec elements belonging to 
type I, II, III, which in the particular case of SCCmec types II and III are known to carry 
additional antimicrobial resistance traits (29, 81). 
 
According to the SENTRY Antimicrobial Surveillance Program, between 1997 and 
2003, the global MRSA prevalence in hospitals was 23% in Australia, 67% in Japan, 
40% in South America, 36% in USA and 23% in Europe (15, 45, 71, 182). 
More recently, in Europe, the MRSA prevalence in invasive disease was 17.5% and 
seems to be decreasing or at least stabilizing, however with proportions ranging from 
0.5 % to 52.2 %, with Portugal as the country with the highest prevalence of MRSA in 
healthcare-associated infections (57). 
Several studies have addressed the topic of the origin of the major MRSA clones. The 
first theory, designated the single-clone theory, proposes that all MRSA descended from 
a single ancestral S. aureus strain that acquired SCCmec once (98). However this 
hypothesis was quickly dismissed and replaced by the multi-clone theory, according to 
which MRSA emerged from repeatedly acquisitions of SCCmec by different S. aureus 
genetic lineages and that subsequently disseminated (55). 
 
18 
The study wherein the first SCCmec acquisition was discovered was a study by 
Crisóstomo et al. (39), where MSSA and early MRSA strains isolated in 1950/1960 in 
Denmark and the United Kingdom (UK) were analyzed. This study showed that MSSA 
strains had gradually accumulated resistance determinants in parallel to antimicrobial 
introduction in therapeutics. Moreover it was shown that the early MRSA (ST250-I, the 
Archaic clone) and MSSA strains (belonging to CC8) had a similar background. 
Furthermore, one of the major contemporary MRSA clones (ST247-I, the Iberian clone) 
was found to be a SLV of ST250, suggesting it was a direct descendant of the archaic 
clone. 
However, as Enright et al (55) described later, other events of acquisition occurred in 
genetic backgrounds not related to CC8 during S. aureus evolutionary history. By 
studying a wide collection of MRSA and MSSA strains, isolated in 20 countries 
between 1961 and 1999, by MLST and SCCmec typing, these authors demonstrated that 
the major MRSA clones could be grouped into five CCs: CC5, 8, 22, 30 and 45. 
Moreover, according to their data SCCmec elements appear to have been acquired by S. 
aureus strains with a distinct genetic background at least 20 times as suggested by the 
presence of different SCCmec elements within the same ST (157). More recently, a 
study by Nubel et al. (136) proposed that the SCCmec element was imported much 
more frequently than previously suggested, and that MRSA apparently emerged locally 
in multiple occasions. Moreover, the same authors suggest that MRSA geographical 
dispersal was limited, however this conclusion is not consensual.  
Additionally, Enright et al. (55) proposed a pattern of descent within the major MRSA 
genetic backgrounds, confirming the findings of Crisóstomo et al. (39)  according to 
which ST250-MSSA, a successful MSSA lineage of CC8, was the ancestor of the first 
MRSA, ST250-I (Archaic clone), as well as of other major nosocomial MRSA 
pandemic lineages such as ST8-IV, ST247-I (Iberian clone) and also ST239-III 
(Brazilian/Hungarian clone). Other major international EMRSA clones such as ST5-II 
(New York/Japan clone), ST22-IVh (EMRSA-15 clone), ST30-IV, ST36-II (EMRSA-
16) and ST45-IV (Berlin clone) were formed within the major five CC and all derived 
from epidemic MSSA lineages that had acquired SCCmec in different occasions (55). 
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ST239-III is one of the most epidemic MRSA clones and also one the better studied. 
Hospital epidemics caused by this clone are well documented all over Europe and South 
America during the 1980s and 1990s and Asia and Middle East in the last decade. 
ST239 was the first bacterial hybrid to be identified in nature. Its chromosome appears 
to have evolved from the homologous recombination of a 557-kb fragment of the ST30 
chromosome with the chromosome of a ST8 strain, representing a distinct branch of 
CC8 (156). A high genetic diversity has been associated to ST239-III, namely a high 
number of different PFGE macrorestriction patterns have been found associated to this 
clone (38, 119). Genetic diversity was also apparent when isolates of ST239-III clone 
from different time periods and geographic locations were analyzed by whole genome 
sequencing. This study demonstrated that ST239 evolved vary rapidly (1 SNP each 6 
weeks), and could be further discriminated into three clades that seem to have evolved 
within a specific geographic region (Europe, South America and Asia). However, 
events of intercontinental spread were also observed to have occurred. Interestingly in 
Portugal both events appear to have taken place. The Portuguese and the Brazilian 
clones, two clones known to have dominated in Portuguese hospitals during the 1990s, 
both belonging to ST239 but that could be distinguished by PFGE, seem to have 
different origins. While the Brazilian clone most probably resulted from the 
introduction of a South American variant in Portugal, the Portuguese clone probably 
was created in Portugal or elsewhere in Europe (77). 
In Table 3 are represented the major healthcare-associated MRSA clonal lineages 
currently spread worldwide. 
Table 3 – Major HA-MRSA clones currently disseminated worldwide. 
HA-MRSA clone ST CC SCCmec 
New York/Japan 5 5 II 
Pediatric 5 5 IV/VI 
Iberian 247 8 I 
Brazilian/Hungarian 239 8 III 
EMRSA-15 22 22 IV 
EMRSA-16 36 30 II 
Berlin 45 45 IV 
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Although MRSA are usually very clonal, their epidemiology has been shown to be 
highly dynamic. In the same geographic region, or single hospitals, it has been 
frequently observed that the prevalent HA-MRSA changes over time. This was the case 
in Hungary where, between 1994 and 2004, ST239-III was replaced by both ST5-II and 
ST228-I; or in Portugal were several clonal waves were documented over a 16-year 
period (4, 34). 
Particularly in Portugal, from 1990 through 2006, several important epidemiological 
events took place in the Portuguese hospital with the replacement of the Portuguese 
clone (ST239-III variant) by the Iberian clone (ST247-IA) in 1992-1993; the emergence 
of the Brazilian clone in 1992 (ST239-III/IIIA) and its rapid dissemination in the 
following years, becoming the dominant clone between 1996 and 2000 (5). 
Subsequently, in 2001, the Brazilian clone was massively replaced by the EMRSA-15 
clone (ST22-IVh), which became widespread in numerous Portuguese hospitals (4, 11), 
being the major clone in several of them. Furthermore, since its first report in Portugal 
as a single isolate, in 2005 (11), the New York/Japan clone (ST5-II) seemed to gain a 
foothold in Portuguese hospitals, representing the second major clone encountered in 
2006 (4), and being suggested as the possible new leading clone in a near future. 
 
1.8.2 The emergence and epidemiology of community-associated MRSA (CA-
MRSA) 
 
After the global spread of MRSA in the nosocomial setting, a change in the MRSA 
epidemiology occurred in the mid- and late 1990s. The MRSA, once confined to the 
hospitals, began to cause infections in the community in otherwise healthy people (27, 
41, 68, 79). 
Community-acquired or community associated MRSA (CA-MRSA) infections were 
first reported in Aboriginal patients in remote communities from Western Australia in 
1993 (186). However, CA-MRSA were only recognized as a new public health threat 
when four healthy children died from sepsis and necrotizing pneumonia in the USA in 
1998 (27). 
According to the Center for Disease Control and Prevention (CDC), MRSA strains 
isolated in an outpatient setting or from patients within 48 hours of hospital admission 
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should be considered CA-MRSA. Furthermore, these patients must have no medical 
history of MRSA infection or colonization (<1 year from infection), no recent 
hospitalization (e.g. surgery), admission to a nursing home or dialysis and the patient 
should not have permanent indwelling devices, such as catheters or other medical 
invasive devices (http://www.cdc.gov/mrsa/diagnosis/index.html). However, several 
other definitions of CA-MRSA have been published, mostly based on the timing of the 
isolation of MRSA relatively to the time of admission, with or without assessment of 
healthcare–associated risk factors; or by the absence of risk factors for healthcare 
associated MRSA (132, 162).  
The type of population affected by CA-MRSA and the clinical syndromes presented are 
different when compared to HA-MRSA. Some groups seem to be at a higher risk for 
CA-MRSA infections, namely children and young people, residents of inner city 
neighborhoods, Native American (NA) and Pacific Islander populations, incarcerated 
and military populations, athletes, people of low socioeconomic status, men who have 
sex with men, HIV patients, injecting and intranasal drug users, veterinarians, livestock 
handlers and pet owners (41). CA-MRSA has been mostly associated with skin and soft 
tissue infections although it can cause more serious infections as necrotizing 
pneumonia, necrotizing fasciitis, severe sepsis, folliculitis, cellulitis, impetigo, 
pyomyositis and myositis, septic arthritis, osteomyelitis, sepsis, and endocarditis (41). 
CA-MRSA differs both genetically and phenotypically from HA-MRSA. Frequently, 
CA-MRSA isolates carry smaller SCCmec elements, usually type IV, V and VII and are 
resistant to fewer non-ß-lactam classes of antimicrobials. Also, CA-MRSA clones have 
been strongly associated with PVL, which is thought to contribute to the pathogenesis 
of these clones. Besides PVL, other virulence factors like ACME, phenol-soluble 
modulins (PSMs) and -toxin may be relevant in CA-MRSA infections (48-50, 101, 
147, 196). 
In the beginning of the emergence of CA-MRSA, each genetic background of PVL-
positive CA-MRSA clones that were disseminated worldwide could be associated to a 
specific continent, i.e., ST1 and ST8 clones in the USA, the ST30 clone in Australia and 
the ST80 in Europe (192). 
Nowadays, CA-MRSA clones are not restrained to a specific geographic region 
anymore and five major PVL-positive CA-MRSA clones have disseminated worldwide: 
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ST1-IV clone (Asia, Europe and the USA), ST8-IV clone (Europe and the USA), ST30-
IV clone (Australia, Europe and South America), ST59-V clone (Asia and the USA) and 
the ST80-IV clone (Asia, Europe and the Middle-East). 
Additionally, some minor CA-MRSA clones have been described recently such as ST5-
IV, the ST22-IV clone, the ST37-IV clone, the ST93-IV, the ST377-V and the ST766-
IV. 
Curiously, in the particular case of USA, a country wherein CA-MRSA account for 
59% of SSTI caused by S. aureus, more than 95% of these infections are due to a single 
clone, the USA 300 clone (ST8-IVa) (177). In contrast, CA-MRSA in Europe seem to 
be much more diverse. Not only the USA300 clone (now emerging in this continent) 
but other clones like the European (ST80-IVc), the Taiwan (ST59-V) and the Southwest 
Pacific clone (ST30-IVc) are causes of infection in the community setting (158). The 
reason why Europe has a wider variety of clonal types remains unclear and needs to be 
clarified.  
Noteworthy, there has been an increasing number of reports of healthcare-associated 
infections caused by CA-MRSA clones and MDR CA-MRSA were already reported 
(46, 124), suggesting that CA-MRSA may have already gained a foothold into the 
nosocomial setting (93, 146, 166). 
In the table below are represented the major CA-MRSA clones disseminated 
worldwide: 
Table 4 – Major CA-MRSA clones currently disseminated worldwide. 
CA-MRSA clone ST CC SCCmec 
USA300 8 8 IV 
European 80 80 IV 
Taiwan 59 59 V 
Southwest Pacific 30 30 IV 
USA400 1 1 IV 
 
In Portugal, a country with a high prevalence of MRSA in hospitals, seems to a have a 
low prevalence of MRSA causing infection in the community setting (5%). 
Nevertheless, some of the major CA-MRSA clones described worldwide have already 
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been found such as USA300, ST80 and ST398 or less disseminated clones like ST121 
and ST22. Moreover, multidrug-resistant (MDR) CA-MRSA isolates were already 
reported in Portugal (178). 
Still, it is not quite understood how CA-MRSA have emerged, if SCCmec has been 
acquired by MSSA in the community or if CA-MRSA is derived from HA-MRSA, with 
some studies supporting the two hypothesis (6, 128, 139). 
 
1.8.3 Livestock Associated-MRSA (LA-MRSA) 
 
More recently, a distinct MRSA clone, unrelated to health-care associated and 
community associated MRSA, has been increasingly observed among colonization in 
pigs and in infection in humans, namely pig farmers. This MRSA clone (ST398-IV, 
ST398-V), first identified in the Netherlands in 2003, is characterized by not being 
typeable by PFGE when cut with SmaI, due to the presence of a novel DNA 
methylation enzyme (16, 191). 
This clone has been described in several other countries in Europe, including Denmark, 
Germany, UK and Portugal and in North America (Canada and USA) (73, 92, 109, 117, 
154, 173). Some PVL-positive ST398 have already been found in human infection in 
China (203) and Europe (188, 197), which poses a serious public health problem. 
 
1.8.4 Methicillin-susceptible S. aureus (MSSA) 
 
Several studies have showed the importance of MSSA as a cause of invasive disease 
and that the epidemiological characteristics of infection are comparable to those of 
MRSA infections, namely CA-MRSA infections (123, 129, 148, 184). 
In a recent survey, on the distribution of S. aureus causing invasive disease in Europe 
between September 2006 and February 2007 revealed that, compared to MRSA, MSSA 
are genetically more diverse and more geographically dispersed (70). 
Furthermore, PVL has been increasingly found associated with some MSSA lineages, 
namely ST121 (128, 155). In a recent study, evaluating the global distribution and 
evolution of PVL among MSSA, it has been shown that most of the predominant CA-
MRSA clones share the same genetic background as PVL-positive MSSA lineages. 
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Also, PVL-positive MSSA are disseminated worldwide, perhaps having started to 
gradually replace the other MSSA lineages unrelated to CA-MRSA in the last two 
decades. These findings suggest that PVL-positive MSSA lineages may act as a 
reservoir for the emergence of CA-MRSA clones (155). 
Among the MSSA clonal lineages disseminated worldwide, some appear to share the 
same genetic background with well-known MRSA clones such as CC5, CC8, CC22, 
CC30 and CC45 (67, 72, 74, 137), whereas others have genetic backgrounds only 
observed among the MSSA population such as CC7, ST9, CC12, ST15, CC25, CC51, 
and CC101 (3, 72, 99). This may be explained by the fact that some genetic 
backgrounds seem to be more favorable to the acquisition and maintenance of mecA 
gene than others (90).  
 
In Portugal, a study from 2005 (3) showed that the MSSA lineages found both in 
hospital and in the community, the ST30, ST34 and ST45 lineages, shared the same 
genetic background of some international MRSA pandemic clones, such as the 
EMRSA-16, New York/Japan, Pediatric and Berlin clones, but that at that time still had 
not been detected in Portugal. The exception was ST5 that shared the same genetic 
background with the MRSA Pediatric clone (ST5-IV), which had been already reported 
in Portugal (161). 
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1.9 Aims of the Thesis 
 
According to European Antimicrobial Resistance Surveillance Network (EARS-Net) 
report of 2010, Portugal presents one of the highest MRSA prevalence (52.2%) in 
nosocomial infections in Europe.  
In Portugal at least three clonal replacement events occurred over a 16-year period (4), 
suggesting that continuous surveillance is essential to be able to act on infection control 
in an informed manner. In Hospital Santa Maria, a major central hospital in Portugal, 
the frequency of MRSA has sharply increased from 30% in 1993 to 49% in 2010, but 
the reasons lying behind this increase are not known. 
On the other hand the epidemiology of MRSA in the community in Portugal is not well 
known. A few episodes of infection caused by community-associated MRSA have been 
reported and according to a recent study by Tavares et al., the frequency of infection 
caused by CA-MRSA isolates at hospital entrance is relatively low (5%) (178). 
However, the frequency of MRSA causing SSTI, the type of infection most commonly 
associated to CA-MRSA, among patients attending healthcare centers in Portugal, was 
never assessed before.  
In this study we aimed to understand the epidemiological phenomenon that could 
explain the increase in MRSA frequency in Hospital Santa Maria within a 17-year 
period, through the molecular characterization of methicillin-resistant Staphylococcus 
aureus (MRSA) isolates collected in 1993 and 2010 using state-of-the-art typing 
techniques.  
Moreover, we aimed to determine the frequency and clonal nature of MRSA and MSSA 
causing SSTI in patients attending healthcare centers in Portugal, by isolating and 
characterizing at the molecular level S. aureus from SSTI samples collected in nine 
different health-care centers (“Médicos Sentinela” Network). 
Finally we expect to reveal the possible epidemiological links between hospital and 
community by comparing the population structure of MRSA in the two settings in 
equivalent time periods (2010/2011).  
 
26 
Chapter 2. Material and Methods 
 
2.1 Bacterial collections 
 
For the elaboration of this master thesis three distinct collections of Staphylococcus 
aureus were studied. 
Two collections were assembled from the hospital setting in different time periods, 
consisting only of methicillin-resistant Staphylococcus aureus (MRSA) isolates.  
The third collection was assembled from the community setting through the “Médicos 
Sentinela” surveillance network (MS). The collection was constituted by both 
methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) 
recovered from skin and soft tissue infections.  
 
2.1.1 Hospital Setting 
 
Hospital Characteristics: Hospital de Santa Maria is a 1,300-bed tertiary teaching 
hospital integrated in CHLN (Centro Hospitalar Lisboa Norte), providing direct 
healthcare to approximately 350,000 people from the areas of Alvalade, Benfica, 
Loures, Lumiar, Odivelas and Pontinha in Lisbon, but also providing services at a 
regional and national level.  
Bacterial collections: Two MRSA collections were assembled at Hospital de Santa 
Maria in two different periods, seventeen years apart. One collection included 54 
MRSA isolates from inpatients, collected between January and March 1993 from pus 
(50%), blood (22.2%), urine (9.3%), bronchial aspirates (7.4%), sputum (5.6%), 
catheter (3.7%) and pleural fluid (1.8%) (38). A second collection included 520 MRSA 
isolates from inpatients, recovered between January and December 2010 from different 
sources (biopsy, vascular catheter, sputum, nasal exudate, eye exudate, blood culture, 
ascitic fluid, bronchoalveolar lavage, synovial fluid, pus, bronchial secretions and 
urine). All clinical and demographic data were recorded and provided in an Excel file. 
In this study all the MRSA isolates collected in 1993 and a subset of 180 isolates 
collected in 2010 (out of the 520 isolates) were analyzed. The group of 180 isolates was 
selected according to the following criteria: the first fifteen isolates collected in each 
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month, recovered from blood culture, pus and urine. One isolate presented different 
morphologies during processing and storage, which resulted in the duplication of 
HSM526 into HSM526A and HSM526B. From the 181 isolates, 118 (65.2%) were 
from pus; 50 (27.6%) were from blood and 13 (7.2%) were from urine.  
MRSA isolation and identification: S. aureus were isolated at the hospital 
microbiology laboratory using standard procedures and identified as MRSA using the 
automated system VITEK2 Advanced Expert System (BioMérieux, Marcy, L’Étoile, 
France). 
 
2.1.2 Community Setting 
 
“Médicos Sentinela” surveillance network: Médicos Sentinela network is a health 
surveillance system created in late 1980s, constituted by general practitioners at 
healthcare centers scattered throughout Portugal. 
Study design: Nine healthcare centers were enrolled in this study: Centro de Saúde 
(CS) Águeda, CS Aveiro, CS Baltar, CS Braga, CS Cantanhede, CS Lagos, CS 
Mealhada, CS Soure and CS Vila Real. The samples were recovered during one year-
period (between November 2010 and October 2011). The samples recovery was 
performed by the “Médicos Sentinela” clinician with a sterile swab and transported 
within a weak time period to the laboratory of Molecular Genetics, Instituto de 
Tecnologia Química e Biológia (ITQB) in Amies medium supplemented with charcoal 
PS and Viscose (Deltalab, S.L.U, Barcelona, Spain). For each sample, a questionnaire 
assessing risk factors for hospital contact was filled by the clinician and delivered with 
the sample (see Annex 5). All clinical and demographic data were recorded in an Excel 
file.  
Bacterial collection: In this master thesis, 73 swabs collected between November 2010 
and April 2011 were analyzed. In the collection, around 63% of the patients were male 
with a mean age of 68 years old, ranging between 16 to 93 years old. 
Community-Associated MRSA definition: according to the CDC (Centers for Disease 
Control and Prevention) criteria, CA-MRSA infections are defined as an MRSA 
infection in an individual who has had: diagnosis of MRSA made in the outpatient 
setting or by a culture positive for MRSA within 48 hours after admission to the 
hospital; no history of hospitalization, surgery, dialysis, or residence in a long-term care 
 
28 
facility within 1 year of the MRSA culture date; no permanent indwelling catheter or 
percutaneous medical device and no known prior positive culture for MRSA.  
Since there was a lack of information in some fields of the questionnaires assessing the 
fulfillment of these criteria, namely the field assessing a previous colonization/infection 
by MRSA (55% of the cases with no information), the term of CA-MRSA could not be 
directly applied and was substituted by the term CO-MRSA, standing for community-
onset MRSA, as proposed by Salgado et al. (162). Furthermore, CO-MRSA was 
divided in CO-MRSA of patients with healthcare-associated risk factors and CO-MRSA 
of patients without healthcare- associated risk factors. 
 
2.2 Samples processing and storage 
 
2.2.1 Hospital de Santa Maria (HSM) collection 
 
All isolates were previously identified as MRSA by HSM microbiology laboratory, 
conserved in Tryptic Soy Broth (TSB, Bacto
TM
, BBL, Becton Dickinson, Sparks, MD, 
USA) (see Annex 1) with 15% glycerol, and posteriorly transported and stored at ITQB 
as oc – original culture. These oc cultures were inoculated on Tryptic Soy Agar (TSA, 
Difco
TM
, BBL, Becton Dickinson, Sparks, MD, USA) (see Annex 1) and incubated at 
37ºC for at least 16 hours, in order to obtain isolated colonies. If the culture was pure, a 
single colony was selected and plated again on TSA at 37ºC for 16 hours. If the culture 
presented colonies with distinct morphologies, each type of colony was streaked on 
TSA until a pure culture was obtained. The purified bacterial cultures were conserved in 
TSB with 15% glycerol at -80ºC and denominated as d - duplicate, and used for further 
analysis. Additionally, clumping factor and protein A detection was tested in all isolates 
by the latex slide agglutination test Staphytect Plus (Oxoid, Basingstoke, Hampshire, 
England) and the d culture was inoculated in a Mannitol Salt Agar plate (MSA, BBL
TM
, 
Becton Dickinson, Sparks, MD, USA) (see Annex 1) for mannitol fermentation 
confirmation.  
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2.2.2 Médicos Sentinela (MS) collection 
 
The swabs received from each healthcare center were inoculated on Mannitol Salt Agar 
(MSA, BBL
TM
, Becton Dickinson, Sparks, MD, USA) and incubated at 37ºC for 48 
hours. MSA plates were inspected for the medium color change (from red to yellow) 
and colony morphology. All different colony morphologies were picked, plated on TSA 
and incubated at 37ºC for at least 16 hours. These cultures were considered the oc – 
original culture. From the oc, a single colony was selected, plated on TSA and 
incubated at 37ºC for at least 16 hours, until a purified culture was obtained. These 
cultures were considered the d – duplicate. Both oc and d were conserved in TSB plus 
15% glycerol at -80ºC. Additionally, clumping factor and protein A production was 
tested by the latex slide agglutination test Staphytect Plus (Oxoid, Basingstoke, 
Hampshire, England) and the d culture was inoculated on a MSA plate.  
Isolates that fermented mannitol and produced clumping factor and protein A were 
included in the study. When the latex slide agglutination test produced inconclusive 
results, the production of coagulase was tested using the BD BBL Coagulase plasma, 
Rabbit test (Becton Dickinson, Sparks, Maryland, USA).  
From a total of 73 swabs collected between November 2010 and April 2011, 40 S. 
aureus were isolated and included in this study. 
 
2.3 Phenotypic characterization of Staphylococcus aureus from the 
community setting 
 
2.3.1 Antibiotic susceptibility testing 
 
All S. aureus isolates from MS collection were tested for antimicrobial susceptibility 
trough disk diffusion method (Kirby-Bauer) according to Clinical and Laboratory 
Standards Institute (CLSI) guidelines from 2008. The antibiotics to which the isolates 
were tested were: Oxacillin (OX), Erythromycin (E), Clindamycin (DA), Linezolid 
(LZD), Ciprofloxacin (CIP), Quinupristin-dalfopristin (QD), Sulfamethoxazole-
Trimethoprim (SXT), Penicillin (P), Tetracyclin (TE), Fusidic Acid (FD), Rifampicin 
(RD), Vancomycin (VA) and Gentamycin (CN). In the case of Fusidic Acid, in which 
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the clinical breakpoints for the antibiotic tested were not defined in CLSI, the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines from 2011 
were used. 
Bacterial suspensions were prepared in a sterile saline solution of 0.85% NaCl and 
adjusted to a turbidity of 0.5 McFarland (1x10
8
 CFU/ml). The bacterial suspensions 
were inoculated on Mueller-Hinton II agar (MHA, BBL
TM
, Becton Dickinson, Sparks, 
MD, USA) (see Annex 1) and incubated at 37ºC for 24 hours with discs impregnated 
with a known antibiotic concentration (Oxoid, Basingstoke, United Kingdom). The halo 
formed around the disc was measured (in mm) and the isolates were considered 
susceptible (S), intermediate resistant (I) and resistant (R) according to CLSI guidelines 
(Table 5). 
Table 5 – Clinical breakpoints for S. aureus according to CSLI 2008 guidelines. 
Antimicrobial 
Agent 
Antimicrobial 
Concentration 
Halo diameter (mm) 
R I S 
Oxacillin 5 g ≤10 11-12 ≥13 
Erythromycin 15 g ≤13 14-22 ≥23 
Clindamycin 2 g ≤14 15-20 ≥21 
Linezolid 30 g - - ≥21 
Ciprofloxacin 5 g ≤15 16-20 ≥21 
Quinupristin-
Dalfopristin 
15 g ≤15 16-18 ≥19 
Sulfamethoxazole-
Trimethoprim 
25 g ≤10 11-15 ≥16 
Penicillin 10 units ≤28 - ≥29 
Tetracyclin 30 g ≤14 15-18 ≥19 
Fusidic Acid* 10 g ≤24 - ≥25 
Rifampicin 5 g ≤16 17-19 ≥20 
Vancomycin
 
30 g - - ≥15 
Gentamicin 10 g ≤12 13-14 ≥15 
*Following EUCAST guidelines 2011. Legend: R-resistant; I-intermediate-resistant; S-susceptible. 
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In this master thesis, S. aureus isolates were considered multidrug-resistant if they were 
resistant to three or more antimicrobial classes (other than ß-lactam antibiotics). 
 
2.3.2 E-test 
 
E-test (AB BioMérieux, Solna, Sweden) was performed for isolates with a halo 
diameter of 14 mm or less for vancomycin, in order to determine the minimal inhibitory 
concentration (MIC), since the strains with reduced susceptibility to vancomycin can 
not be differentiated from the susceptible strains by the disk diffusion method. The 
bacterial suspensions (0.5 McFarland) were inoculated in Mueller-Hinton agar with 2% 
NaCl and incubated at 37ºC for 24 hours. According to the CLSI guidelines (2008), 
isolates with a MIC ≤ 2 g/ml were considered susceptible; isolates with a MIC 
between 4 and 8 g/ml were considered intermediate-resistant and isolates with a MIC 
≥ 16 g/ml were considered resistant. 
 
2.4 Molecular characterization of Staphylococcus aureus from hospital and 
community 
 
Both collections, from the hospital and community setting, were characterized by a set 
of molecular typing techniques including PFGE, spa typing, MLST, SCCmec typing 
and subtyping. 
 
2.4.1 DNA extraction 
 
Chromosomal DNA was prepared using the Wizard Genomic DNA purification kit 
(Promega, Madison, WI, USA) according to the manufacturer’s instructions with the 
following modifications: the isolates were previously plated on TSA and incubated at 
37ºC overnight. Three up to four colonies were resuspended in 100 l of 50 mM EDTA 
(see Annex 1) with 5 l of 10 mg/ml lysostaphin (Ambi Products LLC, New York, 
USA) and 3 l of 10 mg/ml RNase (Sigma-Aldrich, St. Louis, USA) (see Annex 2). 
These suspensions were incubated at 37ºC for 60 minutes and 500 l of Nuclei Lysis 
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Solution were added and the cells were resuspended. The suspensions were again 
incubated at 80ºC for 5 minutes to lyse the cells and cooled to room temperature. 200 l 
of Protein Precipitation Solution were added and the suspension vigorously mixed for 
20 seconds, followed by incubation on ice for 10 minutes. The suspensions were 
centrifuged at 13.000 rpm for 15 minutes at 4ºC. The supernatant containing the DNA 
was transferred to a clean 1.5ml microcentrifuge tube containing 600 l of room 
temperature isopropanol and gently mixed by inversion until the DNA strands formed a 
visible mass. The samples were centrifuged at 13.000 rpm for 15 minutes at 4ºC. The 
supernatants were poured off and the tubes drained on clean absorbent paper. A volume 
of 600 l of 70% ethanol was added and the tubes were gently inverted so the DNA 
pellet was properly washed. The DNA samples were centrifuged again at 13.000 rpm 
for 15 minutes at 4ºC. After the ethanol was carefully aspirated, the tubes were drained 
on clean absorbent paper and the pellet left to air-dry for 15 minutes (alternatively, 
tubes were incubated at 80ºC with the lid open for 1 min). 
Finally, 100 l of 1X TE (see Annex 3) were added to the tubes, to rehydrate the DNA, 
and incubated at 4ºC overnight. The DNA was subsequently stored at -20ºC. 
 
2.4.2 Pulsed Field Gel Electrophoresis 
 
2.4.2.1 DNA agarose disc preparation and PFGE for S. aureus  
 
The protocol used for PFGE analysis was previously described by Chung et al. (32). 
The d cultures were directly inoculated into 5 ml of TSB medium and incubated at 37ºC 
overnight with rotation (TC-7, New Brunswick scientific Co, Edison, New Jersey, 
USA). 
A volume of 500 l of the overnight cultures was transferred to a 1.5 ml 
microcentrifuge tube and centrifuged at 13000 rpm for 2 minutes (Biofugue pico, 
Heraeus Instruments, Germany). The supernatants were discarded with vacuum and the 
pellets were resuspended in 500 l of PIV (see Annex 3). The suspension was then 
again centrifuged and the supernatants discarded with vacuum. A volume of 200 l of 
PIV was added to each tube and the pellets resuspended. A 1:200 dilution of the 
suspension was prepared and the optical density (620 nm) was measured on the 
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spectrophotometer (Ultraspec III, Pharmacia LKB, United Kingdom). PIV was added to 
each bacterial suspension in order to obtain a final OD of 5.0.  
The agarose discs were prepared by doing a mixture of 1:1 of the bacterial suspensions 
(OD=5) with 1.5% (w/v) low melting agarose (SeaPlaque agarose, FCM Bioproducts, 
Rockland, Maine, USA), both previously incubated at 42ºC. 20 l droplets of this 
mixture were deposited onto a parafilm-coated glass and covered with a microscope 
slide to form a disc-like shape. The discs were incubated at -20ºC for 5 minutes and left 
at room temperature for 10 minutes. Lysis of cells was performed by putting the discs in 
1 ml of EC solution (see Annex 3), 50 g/ml RNase A (Sigma-Aldrich, St. Louis, 
USA), 100 g/ml lysozyme (Sigma-Aldrich, St. Louis, USA) and 50 g/ml lysostaphin 
(Ambi Products LLC, New York, USA) and incubated at 37ºC for at least 5 hours, 
followed by incubation in 500 l of ESP solution (see Annex 3) at 50ºC overnight. 
The discs were washed five times in 1X TE, each time for at least 30 minutes at room 
temperature, and stored at 4ºC in this solution until use. 
Total DNA contained in the agarose disc was restricted with 13.5U of SmaI enzyme in 
1X NEB 4 buffer (New England Biolabs, Beverly, USA). The discs were incubated at 
25ºC overnight. 
The chromosomal DNA fragments were then separated in a 1% agarose gel (Seakem 
LE, Lonza, Rockland, ME, USA) in 0.5X TBE (see Annex 3). The electrophoresis was 
carried out in a CHEF DR III apparatus (Bio-Rad, Hercules, California, USA) with 
0.5X TBE as running buffer. The Lambda Ladder PFG Marker (New England Biolabs, 
Beverly, USA) was used as molecular weight marker. The running conditions were the 
following: 6V/cm with initial pulses of 5 seconds, which increased until 35 seconds, for 
a total run of 23 hours. Next, the gel was stained with a 0.375 g/ml ethidium bromide 
solution (Bio-Rad, Hercules, California, USA) for about 20 minutes followed by 
visualization and data recording under UV light in Gel-Doc XR apparatus (Bio-Rad, 
Hercules, California, USA).  
 
2.4.2.2 Analysis of PFGE macro restriction pattern 
 
PFGE macro restriction patterns were analyzed in Bionumerics software (v4.61 Applied 
Maths, Saint-Martens-Latem, Belgium). Gel photographs were converted to 8-bit 
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grayscale TIFF images and treated for analysis using the resources of Bionumerics 
software. The intra and inter gels PFGE runs were normalized using S. aureus 
NCTC8325 previously loaded in each gel as a reference. Band assignments were 
manually curated after automatic band detection for all gel images, where bands ranging 
between 10kb and 674kb were considered for analysis.  
The similarity of PFGE patterns within and between gels was performed with the 
following settings: optimization of 0.5% and position tolerance of 1.25%. PFGE types 
and subtypes were defined by groups formed at 80% and 95% Dice similarity cutoffs 
respectively, on a dendrogram constructed by the unweighted-pair group method using 
average linkages (UPGMA). For identification to each PFGE type a capital letter was 
attributed and to each subtype a numerical number was also attributed. 
The groups defined at these thresholds were previously shown to approximate those 
defined using Tenover’s criteria for visual PFGE type definition (26, 58, 115, 180). 
 
2.4.3 mecA gene detection 
 
The presence of mecA gene in the “Médicos Sentinela” S. aureus isolates was 
performed by PCR with the primers mecA P4 and mecA P7, as previously described 
(141). The PCR mixture was prepared in a volume of 50 l, as follows: 5 ng of template 
DNA, 1X GoTaq Flexi PCR Buffer (Promega, Wisconsin, USA), 1.5mM MgCl2  
(Promega, Wisconsin, USA), 160 M dNTPs (Bioron, Ludwigshafen, Germany), 0.4 
M of each primer and 1.25U of GoTaq Flexi DNA polymerase enzyme (Promega, 
Wisconsin, USA). The amplification reaction was carried out in a PCR apparatus 
(Professional Standard Thermocycler, Biometra, Ludwigshafen, Germany) with the 
following conditions: initial denaturation at 94ºC for 4 minutes, amplification of 30 
cycles (denaturation at 94ºC for 30 seconds, annealing at 55ºC for 30 seconds and 
extension at 72ºC for one minute), final extension at 72ºC for 10 minutes, and kept at 
16ºC in the apparatus until stored at 4ºC. Whenever unspecific bands were detected 
isolates were retested with a higher annealing temperature (58ºC). For all reactions S. 
aureus COL strain was used as a positive control. 
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PCR products (10 l) were run in a 1% agarose gel, with 0.1 g/ml ethidium bromide, at 
5 V/cm for one hour. The PCR products were visualized under UV light in Gel-Doc XR 
apparatus (Bio-Rad, Hercules, California, USA). 
 
2.4.4 spa typing 
 
spa typing was performed on representative isolates of each PFGE type. The 
amplification of spa polymorphic X region was accomplished by PCR as described (2) 
and the primers used were 1113F and 1514R. The reaction mixture was prepared in a 
final volume of 50 l as follows: 5 ng of template DNA, 1X SUPER Tth PCR buffer 1 
with 1.5 mM MgCl2 (HT Biotechnology, Cambridge, United Kingdom); 200 M 
dNTPs (Bioron, Ludwigshafen, Germany), 0.1 M of each primer and 1.25 U of 
SUPER Tth DNA polymerase (HT Biotechnology, Cambridge, United Kingdom). The 
amplification reaction was carried out in a PCR apparatus (Professional Standard 
Thermocycler, Biometra, Ludwigshafen, Germany) in the following conditions: initial 
denaturation at 80ºC for 5 minutes, amplification in 35 cycles (denaturation at 94ºC for 
45 seconds, annealing at 60ºC for 45 seconds and extension at 72ºC for one minute and 
30 seconds), final extension at 72ºC for 10 minutes and kept at 16 ºC in the apparatus 
until stored at 4ºC. For one isolate amplification was not achieved with the conditions 
described above and, for that reason, primers spa F2 and spa R1 were used with the 
following program: initial denaturation at 94ºC for 10 minutes, amplification in 30 
cycles (denaturation at 94ºC for 30 seconds, annealing at 60ºC for 30 seconds and 
extension at 72ºC for 30 seconds) and final extension at 72ºC for 10 minutes (97). 
 The PCR products (2 l) were run in a 1% agarose gel, with 0.1 g/ml ethidium 
bromide, at 5 V/cm for 30 minutes. The PCR products were visualized under UV light 
in Gel-Doc XR (Bio-Rad, Hercules, California, USA) and purified by column, by single 
tube or a 96 well plate, according to the number of samples. The purified PCR products 
were then sent to capillary sequencing (Macrogen Inc., Seoul, South Korea).  
The obtained sequences were analyzed in a software program named Ridom StaphType 
(v2.2.1, Ridom GmbH, Münster, Germany). To each different repeat is given an 
alphanumerical code and to the combination of these repeats is assigned a specific spa 
type. 
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The BURP (Based Upon Repeat Pattern) algorithm (Ridom StaphType software) was 
applied to all spa typing data in order to define spa clonal complexes (spa CC). The 
parameters used for analysis were: exclude spa types shorter than 5 repeats; and spa 
types are clustered if the cost between the members in the same group is equal or less 
than 6 (118). Last accessed at September 27, 2011. 
 
2.4.5 Multilocus Sequence Typing (MLST) 
 
MLST was performed as previously described (54) in representative isolates of each spa 
type for HSM collection and in representative MRSA isolates of each spa type and 
some priority MSSA isolates (with a new spa type or spa types that were not described 
in literature) of MS collection. The reaction mixture was prepared in a final volume of 
50 l as follows: 5 ng of template DNA, 1X SUPER Tth PCR buffer 1 with 1.5 mM 
MgCl2 (HT Biotechnology, Cambridge, United Kingdom); 160 M dNTPs (Bioron, 
Ludwigshafen, Germany), 0.4 M of each primer and 1.25 U of SUPER Tth DNA 
polymerase (HT Biotechnology, Cambridge, United Kingdom). The amplification 
reaction was carried out in a PCR apparatus (Professional Standard Thermocycler, 
Biometra, Ludwigshafen, Germany) in the following conditions: initial denaturation at 
94ºC for 4 minutes, amplification in 30 cycles (denaturation at 94ºC for 30 seconds, 
annealing at 55ºC for 30 seconds and extension at 72ºC for 30 seconds), final extension 
at 72ºC for 10 minutes and kept at 16ºC in the apparatus until stored at 4ºC. Whenever 
needed the annealing temperature was decreased to 50ºC in order to obtain 
amplification. 
The PCR products (2 l) were run in a 1% agarose gel, with 0.1 g/ml ethidium 
bromide, at 5 V/cm for 30 minutes. The PCR products were then visualized and 
recorded under UV light in Gel-Doc XR (Bio-Rad, Hercules, California, USA), and 
purified by column, by single tube or a 96 well plate, according to the number of 
samples. The purified PCR products were sent to capillary sequencing (Macrogen Inc., 
Seoul, South Korea). 
The sequences were analyzed using the software SeqMan (v5.03, DNASTAR, Inc.) and 
submitted to the MLST database (http://saureus.mlst.net) for allele attribution. Sequence 
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type (ST) attribution was achieved by submitting to the database the allelic profile for 
each strain, containing the allele number of each gene analyzed. 
The eBURST algorithm (eBURST v.3) was applied to all MLST data in order to assign 
MLST clonal complexes (CC) (http://eburst.mlst.net). Last accessed at September 27, 
2011. 
 
2.4.6 Staphylococcal cassette chromosome mec (SCCmec) typing  
 
SCCmec typing was performed using different typing methods whenever it was deemed 
necessary. 
 
2.4.6.1 SCCmec typing by multiplex PCR 
 
SCCmec typing was performed for all MRSA isolates. The determination of SCCmec 
structure was performed by multiplex PCR as previously described (122). The 
following strains were used as controls: COL (SCCmec type I), N315 (SCCmec type II), 
ANS46 (SCCmec type III), MW2 (SCCmec type IVa), WIS (SCCmec type V) and 
HDE288 (SCCmec type VI). The PCR mixture was prepared in a final volume of 50 l, 
as follows: 5 ng of template DNA, 1X AmpliTaq PCR buffer with 1.5 mM MgCl2 
(Applied Biosystems, Roche, Branchburg, New Jersey, USA); 160 M dNTPs (Bioron, 
Ludwigshafen, Germany); 0.2 M of primers kdp F1 and kdp R1; 0.4 M of primers 
CIF2 F2, CIF2 R2, RIF5 F10, RIF5 R13, SCCmec III J1F, SCCmec III J1R, SCCmec V 
J1 F, and SCCmec V J1 R; 0.8 M of primers mecI P2, mecI P3, dcs F2, dcs R1, mecA 
P4, mecA P7, ccrB2 F2, ccrB2 R2, ccrC F2, and ccrC R2; and 1.25 U of Amplitaq DNA 
polymerase enzyme (Applied Biosystems, Roche, Branchburg, New Jersey, USA). The 
amplification reaction was carried out in a PCR apparatus (Professional Standard 
Thermocycler, Biometra, Ludwigshafen, Germany) with the following conditions: 
initial denaturation at 94ºC for 4 minutes, amplification in 30 cycles (denaturation at 
94ºC for 30 seconds, annealing at 53ºC for 30 seconds and extension at 72ºC for one 
minute), final extension at 72ºC for 4 minutes, and kept at 16ºC in the apparatus until 
stored at 4ºC. 
PCR products (10 l) were resolved in a 3% agarose gel (Seakem LE, Lonza, Rockland, 
ME, USA) in 0.5X TBE buffer, containing 0.1 g/ml of ethidium bromide, at 4 V/cm 
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for 2.5 hours (BioRad, Hercules, CA, USA). The PCR products were then visualized 
and recorded under UV light in Gel-Doc XR apparatus (Bio-Rad, Hercules, California, 
USA). 
 
2.4.6.2 SCCmec IV subtyping 
 
All isolates carrying SCCmec IV were further characterized by multiplex PCR as 
previously described (121) to determine the SCCmec IV subtype. The following strains 
were used as controls: MW2 (SCCmec type IVa), 8/6-3P (SCCmec type Ivb), Q2314 
(SCCmec type Ivc), JCSC4469 (SCCmec type Ivd), M03-68 (SCCmec type Ivg) and 
HAR22 (SCCmec type Ivh). The PCR mixture was prepared in a final volume of 50 l, 
as follows: 5 ng of template DNA, 1X SUPER Tth PCR buffer 1 with 1.5 mM MgCl2 
(HT Biotechnology, Cambridge, United Kingdom); 160 M dNTPs (Bioron, 
Ludwigshafen, Germany); 0.2 M of primers J1 IVa F, J1 IVa R, J1 Ivb F and J1 Ivb R; 
0.4 M of primers ccrB2 F, J1 Ivc F and J1 Ivc R; 0.8 M of primers ccrB2 R, J1 Ivd F 
and J1 Ivd R; 0.9 M of primers J1 Ivg F and J1 Ivg R and 1.8 M of primers J1 Ivh F 
and J1 Ivh R; and 1.25 U of SUPER Tth DNA polymerase (HT Biotechnology, 
Cambridge, United Kingdom). The amplification reaction was carried out in a PCR 
apparatus (Professional Standard Thermocycler, Biometra, Ludwigshafen, Germany) 
with the following conditions: initial denaturation at 94ºC for 4 minutes, amplification 
in 35 cycles (denaturation at 94ºC for 30 seconds, annealing at 48ºC for 30 seconds and 
extension at 72ºC for two minutes), final extension at 72ºC for 4 minutes, and kept at 
16ºC in the apparatus until stored at 4ºC. 
PCR products (20 l) were resolved in a 2% agarose gel (Seakem LE, Lonza, Rockland, 
ME, USA) in 1X TAE buffer (see Annex 3), containing 0.1 g/ml ethidium bromide, at 
5 V/cm for one hour and visualized under UV light in Gel-Doc XR apparatus (Bio-Rad, 
Hercules, California, USA). 
 
2.4.6.3 mec complex class and ccrAB type determination 
 
The mec complex class was defined by the structure of mec complex components (mecA 
gene and its regulatory genes, mecI and mecR1) as previously described (139). Such 
 
39 
approach was used whenever no SCCmec type could be assigned through the PCR 
multiplex strategy.  
The control strains used were S. aureus ANS46 (mec gene complex class A) and COL 
(mec gene complex class B). The PCR mixture was prepared in a final volume of 50 l, 
as follows: 5 ng of template DNA, 1X AmpliTaq PCR buffer with 1.5 mM MgCl2 
(Applied Biosystems, Roche, Branchburg, New Jersey, USA), 160 M dNTPs (Bioron, 
Ludwigshafen, Germany), 0.4 M of primers mI4 and mI3 (mec gene complex class A) 
or mA6 and IS5 (mec gene complex class B) and 1.25 U of Amplitaq DNA polymerase 
enzyme (Applied Biosystems, Roche, Branchburg, New Jersey, USA). Both 
amplification reactions for mec gene complex A and B were carried out in a PCR 
apparatus (Professional Standard Thermocycler, Biometra, Ludwigshafen, Germany) 
with the following conditions: initial denaturation at 94ºC for 4 minutes, amplification 
in 30 cycles (denaturation at 94ºC for 30 seconds, annealing at 55ºC for 1 minute and 
extension at 72ºC for 2 minutes), final extension at 72ºC for 10 minutes, and kept at 
16ºC in the apparatus until stored at 4ºC. 
The determination of ccrAB allotypes was performed by multiplex PCR as previously 
described (139). The following S. aureus strains were used as controls: COL (ccrAB 
type 1), N315 (ccrAB type 2) and ANS46 (ccrAB type 3). The PCR mixture was 
prepared in a final volume of 50 l, as follows: 5 ng of template DNA, 1X AmpliTaq 
PCR buffer with 1.5 mM MgCl2 (Applied Biosystems, Roche, Branchburg, New Jersey, 
USA), 240 M dNTPs (Bioron, Ludwigshafen, Germany), 0.4 M of primer 1, 0.8 
M of primers 2, 3, c, and 1.25 U of Amplitaq DNA polymerase enzyme (Applied 
Biosystems, Roche, Branchburg, New Jersey, USA). The amplification reaction was 
carried out in a PCR apparatus (Professional Standard Thermocycler, Biometra, 
Ludwigshafen, Germany) with the following conditions: initial denaturation at 94ºC for 
4 minutes, amplification in 30 cycles (denaturation at 94ºC for 30 seconds, annealing at 
55ºC for 1 minute and extension at 72ºC for 2 minutes), final extension at 72ºC for 10 
minutes, and kept at 16ºC in the apparatus until stored at 4ºC. 
The PCR products (10 l) were run in a 1% agarose gel in 1X TAE buffer, containing 
0.1 g/ml of ethidium bromide, at 5 V/cm for one hour (BioRad, Hercules, CA, USA). 
The PCR products were then visualized and recorded under UV light in Gel-Doc XR 
apparatus (Bio-Rad, Hercules, California, USA). 
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2.4.6.4 ccrAB4 typing 
 
For all the isolates that could not been assigned a ccrAB allotypes the screening for the 
presence of ccrAB type 4 was performed (142). The strain used as control was S. aureus 
HDE288 (ccrAB4; SCCmec VI). The PCR mixture was prepared in a final volume of 50 
l, as follows: 5 ng of template DNA, 1X AmpliTaq PCR buffer with 1.5 mM MgCl2 
(Applied Biosystems, Roche, Branchburg, New Jersey, USA), 160 M dNTPs (Bioron, 
Ludwigshafen, Germany), 0.4 M of primers ccrB4 F and ccrB4 R, and 1.25 U of 
Amplitaq DNA polymerase enzyme (Applied Biosystems, Roche, Branchburg, New 
Jersey, USA). The amplification reaction was carried out in a PCR apparatus 
(Professional Standard Thermocycler, Biometra, Ludwigshafen, Germany) with the 
following conditions: initial denaturation at 94ºC for 10 minutes, amplification in 30 
cycles (denaturation at 94ºC for 30 seconds, annealing at 55ºC for 1 minute and 
extension at 72ºC for 2 minutes), final extension at 72ºC for 4 minutes, and kept at 16ºC 
in the apparatus until stored at 4ºC. 
The PCR products (10 l) were run in a 1% agarose gel in 1X TAE buffer, containing 
0.1 g/ml of ethidium bromide, at 5 V/cm for one hour (BioRad, Hercules, CA, USA). 
The PCR products were then visualized and recorded under UV light in Gel-Doc XR 
apparatus (Bio-Rad, Hercules, California, USA). 
 
2.4.7 Screening of virulence factors 
 
2.4.7.1 Detection of Panton-Valentine Leukocidin gene (PVL) 
 
The presence of Panton-Valentine Leukocidin genes, lukS-PV and lukF-PV, was 
detected by PCR as described by Lina et al. (104). The strain used for positive control 
of pvl gene was S. aureus MW2 and the primers were PVL-1 and PVL-2. The PCR 
mixture was prepared in 50 l of reaction mixture, as follows: 5 ng of template DNA, 
1X GoTaq Flexi PCR Buffer (Promega, Wisconsin, USA), 1.5mM MgCl2  (Promega, 
Wisconsin, USA), 160 M dNTPs (Bioron, Ludwigshafen, Germany), 0.4 M of each 
primer and 1.25U of GoTaq Flexi DNA polymerase enzyme (Promega, Wisconsin, 
USA). The amplification reaction was carried out in a PCR apparatus (Professional 
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Standard Thermocycler, Biometra, Ludwigshafen, Germany) in the following 
conditions: initial denaturation at 94ºC for 5 minutes, amplification in 25 cycles 
(denaturation at 94ºC for 30 seconds, annealing at 55ºC for 30 seconds and extension at 
72ºC for one minute), final extension at 72ºC for 7 minutes and kept at 16ºC in the 
apparatus until stored at 4ºC. The PCR products (10 l) were run in a 1% agarose gel in 
1X TAE buffer, containing 0.1 g/ml ethidium bromide, at 5 V/cm for one hour 
(BioRad, Hercules, CA, USA). The PCR products were visualized under UV light in 
Gel-Doc XR (Bio-Rad, Hercules, California, USA). 
 
2.4.7.2 Detection of arginine catabolic mobile element (ACME) 
 
The presence of ACME was determined by the amplification of arcA and opp3 genes by 
PCR. The primers used were arcA F and arcA R for arcA gene (47) and AIPS.45 and 
AIPS.46 for opp3 gene (50). The strain used as positive control was a S. aureus 
USA300 strain. The reaction mixture was prepared in a final volume of 50 l as 
follows: 5 ng of template DNA, 1X GoTaq Flexi PCR Buffer  (Promega, Wisconsin, 
USA), 1.5 mM MgCl2  (Promega, Wisconsin, USA), 160 M dNTPs (Bioron, 
Ludwigshafen, Germany), 0.4 M of each primer and 1.25U of GoTaq Flexi DNA 
polymerase enzyme (Promega, Wisconsin, USA). The amplification reaction of arcA 
gene was carried out in a PCR apparatus (Professional Standard Thermocycler, 
Biometra, Ludwigshafen, Germany) in the following conditions: initial denaturation at 
95ºC for 4 minutes, amplification in 30 cycles (denaturation at 95ºC for 1 minute, 
annealing at 55ºC for 1 minute and extension at 72ºC for 2 minutes), final extension at 
72ºC for 10 minutes and kept at 16ºC in the apparatus until stored at 4ºC. The 
amplification reaction of opp3 gene was also carried out in the following conditions: 
initial denaturation at 95ºC for 4 minutes, amplification in 30 cycles (denaturation at 
95ºC for 1 minute, annealing at 57ºC for 1 minute and extension at 72ºC for 2 minutes), 
final extension at 72ºC for 10 minutes and kept at 16 ºC in the apparatus until stored at 
4ºC. Whenever unspecific bands appeared, the annealing temperature was raised until 
59ºC. The PCR products (10 l) were run in a 1% agarose gel in 1X TAE buffer, 
containing 0.1 g/ml ethidium bromide, at 5 V/cm for one hour (BioRad, Hercules, CA, 
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USA) and visualized under UV light in Gel-Doc XR (Bio-Rad, Hercules, California, 
USA). 
 
2.4.8 PCR products purification and sequencing 
 
The great majority of the PCR products were purified with the High Pure 96 UF 
cleanup Kit (Roche Applied Science, Mannheim, Germany) linked to a vacuum 
manifold, according to the manufacturer’s instructions. PCR amplification products 
were transferred to a High Pure UF Cleanup plate and vacuum was applied until all 
liquid had passed through the filter membranes in the wells. A volume of 100 l of 
Wash Buffer was added and vacuum was applied once again until all the Wash Buffer 
had passed through the membranes. A volume of 30 l of resuspension buffer was 
added and the plate was incubated for 15 minutes at room temperature. The purified 
PCR amplification products were then transferred to a new 96 well plate and sent to 
capillary sequencing (Macrogen Inc., Seoul, South Korea).  
When the PCR products were in low number, these were purified with High Pure PCR 
products Purification kit (Roche Applied Science, Mannheim, Germany) according to 
the manufacturer’s instructions. 
 
2.5 MRSA clone definition 
 
In this thesis, MRSA clones were defined by their ST and their type of SCCmec as 
proposed by Enright et al.(54). 
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Chapter 3. Results 
 
3.1 Clonal distribution and epidemiology of methicillin-resistant 
Staphylococcus aureus (MRSA) collected from inpatients in the hospital 
setting 
 
3.1.1 Molecular characterization of hospital-associated MRSA isolates from the 
first study period (1993) 
 
The collection of 54 MRSA isolates recovered in 1993 in Hospital de Santa Maria 
(HSM), was characterized by PFGE, spa typing, MLST and SCCmec typing and 
subtyping. During this period, two main clones were identified circulating in HSM: the 
Iberian clone (ST247-I) and the Portuguese clone (ST239-III var), accounting for 
approximately 72% (n=39) and 28% (n=15) of the isolates, respectively (see Figure 2). 
 
 
Figure 2 – MRSA population structure of isolates collected at HSM in 1993 based on MLST, SCCmec 
and PFGE type. 
The Iberian clone, ST247-I, with all isolates belonging to a single PFGE type M (n=39), 
was characterized by spa types t008 and t051. Additionally, all isolates carried SCCmec 
type I, with the exception of a single isolate that was positive for two additional loci 
characteristic of SCCmec types III and V (primers RIF5 F10/RIF5 R13 and ccrC 
72% 
28% 
ST247-I/PFGE type M ST239-IIIvar/PFGE type N&O 
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F2/ccrC R2, respectively when multiplex PCR was used). The assignment of SCCmec 
type I in this isolate was confirmed by the presence of the mec complex class B and 
ccrAB type 1, similarly to the prototype strain for SCCmec type I (COL) that was used 
as positive control as assessed by individual PCR reactions (see Table 6). 
 
The Portuguese clone, ST239-III var, was represented by isolates belonging to two 
different PFGE types, PFGE type N (n=12) and O (n=3), sharing a similarity of 
approximately 77%, and both characterized by spa type t421. All isolates belonging to 
both PFGE types carried an SCCmec type III variant, since no amplification could be 
retrieved from SCCmec type III J1 locus (primer RIF5 F10/RIF5 R13). The assignment 
of SCCmec type III was confirmed by the presence of mec complex class A and ccrAB 
type 3, similarly to prototype strain for SCCmec III (ANS46) that was used as positive 
control (see Table 6). 
 
In order to establish the relatedness between the different isolates, the BURP algorithm 
was applied to spa typing data and spa clonal complexes (spa-CC) were assigned (see 
Figure 3). Both spa types t008 and t051 belong to the same spa-CC, however no 
founder was assumed. Concerning spa type t421, it was considered a singleton, not 
grouping in the spa-CC of t008 and t051 (see Table 5). Furthermore, the separation of 
spa types t008 and t051 and t421 to different spa-CC is in agreement with the fact that 
these spa-CC are grouped into different PFGE types.  
 
 
Figure 3 – BURP analysis of spa types of the isolates belonging to the HSM isolates collected in 1993. 
One spa-CC (008/051) was found with no founder assigned, comprising spa types t008 and t051. Spa 
type t421 was considered a singleton. The black dots correspond to different spa types and related spa are 
linked by lines. 
Similarly to spa algorithm BURP, MLST data can be analyzed by the eBURST 
algorithm to access the clonal complexes (CC) formed by related STs. MLST data were 
analyzed to perform a cluster analysis and a comparison with the whole S. aureus 
MLST database (http://saureus.mlst.net/). Through the eBURST algorithm, ST247 and 
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ST239 were both included into clonal complex 8 (CC8), in which ST8 is the predicted 
founder and ST239 and ST247 are single and double-locus variants of ST8, 
respectively.  
Globally, the results show two distinct clones. Even though both clones belong to CC8, 
they are characterized by distinct PFGE type, spa types, ST and SCCmec types. 
 
All isolates from the 1993 HSM collection were screened by PCR for the presence of 
Panton Valentine Leukocidin (PVL) and the arginine catabolic mobile element 
(ACME). However, none of the isolates carried the genes encoding these virulence 
determinants. 
 
The main characteristics of MRSA isolates from 1993 HSM collection are listed in 
Table 6. 
 
Table 6 – Main characteristics of MRSA isolates from Hospital de Santa Maria collected in 1993. 
PFGE,  
no. isolates (%)  
SCCmec 
 (no. isolates) 
spa 
type 
ST (CC) PVL ACME 
MRSA 
clone 
M, 39 (72.2%) I
1
, (39) 
t008/ 
t051 
247 (8) - - Iberian 
N, 12 (22.2%) III variant, (12) 
t421 239 (8) 
- - 
Portuguese 
O, 3 (5.6%) III variant, (3) - - 
1
One isolate with SCCmec type I variant: presence of mec complex class B and ccrAB type 1 was 
confirmed in simplex PCR, as described in Chapter 2. 
(-) absent. 
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3.1.2 Molecular characterization of hospital-associated MRSA isolates from the 
second study period (2010) 
 
The 181 MRSA isolates collected in HSM in 2010 were also characterized by PFGE, 
spa typing, MLST and SCCmec typing and subtyping. 
From a global point of view, nine MRSA clones were represented in the 2010 HSM 
collection: ST22-IVh (EMRSA-15 clone), ST105-II (New York/Japan clone related), 
ST5-IVc (Pediatric clone), ST125-IVc (Pediatric clone related), ST36-II (EMRSA-16 
clone), ST2246-III (Brazilian clone related), ST1-IVa (USA400 clone related), ST8-IVa 
and ST8-VI (see Figure 4 and Table 7). 
 
 
Figure 4 – MRSA population structure of isolates collected in HSM in 2010 based on MLST, SCCmec 
and PFGE type. 
 
The major clone in the collection, ST22-IVh, the EMRSA-15 clone, accounting for 72% 
of the isolates, was characterized by PFGE type K and carried SCCmec type IVh. 
Additionally, as many as six different spa types were assigned to this clone: t2357 
(n=79), t910 (n=31), t025 (n=7), t032 (n=6), t1467 (n=5) and t1302 (n=1). This clone 
belonged to clonal complex 22 as determined by eBURST. 
72% 
18% 
4% 2% 
1.7% 
1% 
0.5% 
0.5% 
0.5% 
ST22-IVh/PFGE type K ST105-II/PFGE type E & I ST125-IVc/PFGE type I 
ST36-II/PFGE type B ST2246-III/PFGE type F ST1-IVa/PFGE type F 
ST5-IVc/PFGE type I ST8-IVa/PFGE type C ST8-VI/PFGE type C 
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We considered that the second major clonal group was a set of three highly related 
clones; they were related to the New York/ Japan clone (ST5-II) or to the Pediatric 
clone (ST5-IVc) or were single locus variants (SLV) of these clones and all belonged to 
CC5. 
Among this group, the most prevalent clone was ST105-II, accounting for 18% of the 
isolates. Clone ST105-II was characterized by two PFGE types, PFGE type I (n=30) 
and PFGE type E (n=2), that shared a similarity of 77%, which is very close to the 
threshold that was considered to group isolates into the same PFGE type. Additionally 
this clone carried SCCmec type II and was characterized by spa type t002. 
The second most prevalent clone within this group was ST125-IVc, related to the 
Pediatric clone, which accounted for 4% of the isolates. These isolates belonged to 
PFGE type I (n=7), harbored SCCmec type IVc and were characterized by spa type t067 
(n=6) and t002 (n=1).  
Finally in this group, we identified a single isolate of clone ST5-IVc, the Pediatric 
clone. This isolate was characterized by belonging to the PFGE type I, spa type t535 
and carrying the SCCmec type IVc. 
 
Overall, these three clones, ST105-II, ST125-IVc and ST5-IVc, represented 
approximately 22% of the entire collection. 
 
Together, the two major groups of isolates (EMRSA-15 and the group of the three 
different clones related to CC5) accounted for more than 90% of the collection. The 
remaining 6% of the collection comprised five minor clones belonging to four different 
clonal complexes. 
 
Among the minor clones, ST36-II, also known as EMRSA-16, was the most prevalent. 
This clone accounted for 2% of the isolates (n=4) and was characterized by PFGE type 
B, SCCmec type II, spa type t018 and belonged to CC30. 
Another minor clone was ST2246-III, an SLV from the Brazilian clone that accounted 
for 1.7% of the isolates (n=3) and was characterized by PFGE type F, spa type t037 and 
carried SCCmec type III. This clone presented a genetic background (CC8) related to 
the MRSA isolates recovered in 1993 in this same hospital. 
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The ST1-IVa clone, related to the CA-MRSA USA400 clone, accounted for 1% (n=2) 
of the isolates. This clone was characterized by PFGE type F, spa type t127 and carried 
the SCCmec type IVa. Moreover, belonged to the CC15 clonal complex. 
Surprisingly, clones ST2246-III and ST1-IVa were grouped in the same PFGE type, 
although they contained completely distinct spa types and ST. Nevertheless they could 
be clearly separated if a more restrictive cutoff level was considered in PFGE (95% of 
similarity, corresponding to PFGE subtype cut-off). 
 
The remaining minor clones found were ST8-IVc and ST8-VI clones that were 
represented by single isolates each (1%). Both isolates were characterized by PFGE 
type C and belonged to CC8, but while ST8-IVc clone was characterized by spa type 
t008 and carried SCCmec type IVc, ST8-VI clone was characterized by spa type t024 
and carried SCCmec type VI. 
 
Additionally, one isolate did not amplify SCCmec or mecA gene and consequently was 
considered a methicillin-susceptible S. aureus (MSSA). This isolate was the single 
representative of PFGE type A and was associated with spa type t884, which has 
already been reported associated to MSSA isolates (http://spaserver.ridom.de).  
 
Similarly to the 1993 collection, the BURP algorithm was applied to all spa data 
obtained (see Figure 5). 
Four different spa-CC were defined among the 180 MRSA isolates analyzed, grouping 
9 out of the 14 spa types identified. The major spa-CC, grouping all EMRSA-15 
isolates, comprised the spa types t025, t032, t1302, t1467 and t2357, having t032 as the 
predicted founder of the cluster – spa-CC 032. The second largest spa-CC comprised 
spa types t002 and t067, but does not have a founder assigned. The third spa-CC 
comprised spa types t018 and t037 and the fourth comprised spa types t008 and t024, 
neither of them with a founder assigned. Regarding spa type t127, it was considered a 
singleton and was not included in any cluster. Additionally, spa type t535 was excluded 
from analysis due to the fact of being shorter than five repeats. 
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Overall, spa-CC demonstrates a good congruence with PFGE results. The grouping of 
t037 and t018 in the same cluster was surprising, since they apparently belong to 
distinct PFGE types. 
 
 
Figure 5 – BURP analysis of spa data obtained from isolates collected in HSM in 2010. spa types are 
represented by dots and the related spa types are linked by a line. The shade of the line varies according 
to the evolutionary cost between the spa types, where a darker shade represents a lower evolutionary cost. 
The ancestor of spa-CC cluster is represented in blue. 
 
Similarly to HSM 1993 isolates, isolates from HSM 2010 collection were screened by 
PCR for the presence of Panton Valentine Leukocidin and ACME operon, however no 
positive results were obtained. 
 
Of note, no relevant associations were found between the PFGE types/MRSA clonal 
backgrounds and the clinical products or the age groups in the population affected. 
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The main genotypic characteristics of the isolates collected in HSM in 2010 are listed in 
the table below (Table 7). 
 
Table 7 – Molecular characterization of MRSA isolates from Hospital de Santa Maria collected in 2010. 
PFGE type,  
no. isolates (%) 
SCCmec 
(no. isolates) 
spa type  ST (CC) PVL ACME 
K, 129 (71.3%) IVh, (129) 
t025/t032/t910/t1302/ 
t1467/t2357 
22 (22) - - 
I, 38 (21%) 
II, (30) t002 105 (5) 
- - IVc, (7) t067/t002 125 (5) 
IVc, (1) t535 5 (5) 
F, 5 (2.8%) 
III, (3) t037 2246 (8) 
- - 
IVa, (2) t127 1 (15) 
B, 4 (2.2%) II, (4) t018 36 (30) - - 
C, 2 (1.1%) 
IVc, (1) t008 
8 (8) - - 
VI, (1) t024 
E, 2 (1.1%) II, (2) t002 n.d  - - 
n.d - not determined; (-) absent. 
 
3.1.3 Comparison of MRSA population structure in 1993 and 2010 
 
The population structures of MRSA collected from inpatients in 1993 and 2010 differed 
almost completely and no common MRSA clones were found between the two study 
periods. 
While in 1993 ST239-III and ST247-I accounted for all MRSA population, in 2010 the 
ST22-IVh and other additional seven clones were described. Overall, a highest genetic 
diversity was found in the MRSA collected in 2010 than in 1993, namely a high 
diversity was found in terms of PFGE types, SCCmec types, spa types, STs and CCs. 
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3.2 Clonal distribution and epidemiology of Staphylococcus aureus in the 
community – “Médicos Sentinela” surveillance network 
 
3.2.1 Staphylococcus aureus in SSTI 
 
A total of seventy-three swabs were collected from SSTI patients attending nine 
healthcare centers. These patients were in their majority male (63%) with a mean age of 
68 years old (ranging between 16 through 93 years old).  
Among the 73 swabs, 40 S. aureus isolates were isolated (54.8%), of which seven 
carried the mecA gene, which represents an MRSA frequency of 17.5% in the 
collection. The MRSA and MSSA isolates distribution by the several healthcare centers 
is depicted in Figure 6: 
 
 
Figure 6 – MSSA and MRSA isolates distribution by the participant healthcare centers (CS – Centro de 
Saúde). 
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 3.2.2 Questionnaires analysis for healthcare-associated risk factors  
 
For each swab collected a questionnaire was filled in order to access the host risk 
factors. The vast majority of patients presented at least one risk factor: in the last 12 
months approximately 25% of the patients had been hospitalized, at least 12.5% had 
contact with a long-term care facility, 15% had surgery and around 2.5% had been 
subjected to dialysis or had a permanent indwelling catheter. It could be confirmed that 
at least 10% had been previously infected/colonized by MRSA in the last 12 months. 
Additionally, 83% of the patients had taken antibiotics during this period (see Figure 7 
and Annex 5). 
 
Figure 7 – Frequency of healthcare-associated risk factors assessed from the analysis of the 
questionnaires of the 40 S. aureus positive samples. 
 
For the specific case of the seven MRSA isolates, according to the definition criteria 
proposed in the material and methods chapter, four isolates were considered as being 
community-onset MRSA without risk factors, while three were considered as 
community-onset MRSA with risk factors. 
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3.2.3 Antibiotic resistance profile 
 
All MSSA isolates included in this study were characterized for their resistance profile 
against a panel of 13 antibiotics (see Figure 8). Overall, 66.7% (n=22) of the isolates 
were resistant to penicillin (P), 18% (n=6) were resistant to fusidic acid (FD), 12% 
(n=4) were resistant to gentamicin (CN), 12% (n=4) were resistant to tetracycline (TE), 
12% (n=4) were resistant to ciprofloxacin (CIP), 3% (n=1) were resistant to 
erythromycin (E), 3% (n=1) were resistant to sulfamethoxazol-trimethoprim (SXT) and 
3% (n=1) were resistant to rifampicin (RD). Additionally, one isolate (3%) presented an 
intermediate-resistant phenotype to oxacillin. No resistance to clindamycin (DA), 
linezolid (LZD), quinupristin-dalfopristin (QD) or vancomycin (VA) was observed. 
Around 9% of the isolates (n=3) were resistant or presented intermediate-resistance to at 
least 3 different antibiotic classes. Only five MSSA isolates (15%) were susceptible to 
all the antibiotics tested. 
 
 
Figure 8 – Antimicrobial susceptibility of the 33 MSSA isolates collected from SSTI in healthcare 
centers of against a panel of 13 antibiotics. Abbreviations: S, susceptible; R, resistant; I, intermediate-
resistant; OX, oxacillin; E, erythromycin; DA, clindamycin; LZD, linezolid; CIP, ciprofloxacin; QD, 
quinopristin-dalfopristin; SXT, trimethoprim-sulfamethoxazole; P, penicillin; TE, tetracycline; FD, 
fusidic acid; RD, rifampicin; VAN, vancomycin; CN, gentamicin. 
 
The seven MRSA isolates were also tested against a panel of 13 antibiotics (see Table 
8). Overall, all isolates were resistant to penicillin (P) and ciprofloxacin (CIP). Five 
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isolates were resistant to erythromycin (E); four were resistant to clindamycin (DA) 
(three of the isolates presented an inducible resistant phenotype); two were resistant to 
fusidic acid (FD); two were resistant to quinupristin-dalfopristin (QD). No resistance 
was observed to linezolid (LZD), sulfamethoxazol-trimethoprim (SXT), tetracycline 
(TE), rifampicin (RD), vancomycin (VA) or gentamicin (CN). In all isolates oxacillin 
resistance expression was associated to the carriage of the mecA gene, but interestingly, 
one isolate carrying the mecA gene presented a susceptible phenotype to oxacillin. 
 
Although there was no single pattern of antibiotic resistance among MRSA isolates, 
these were in their majority resistant to more antibiotics classes than MSSA isolates.  
All MRSA isolates were resistant to penicillin and ciprofloxacin and the great majority 
(n=5) also to erythromycin. The only isolates resistant to clindamycin and quinupristin-
dalfopristin were also MRSA. Overall, five MRSA isolates were considered multidrug-
resistant. 
 
Table 8 – Resistance profile of the seven MRSA isolates collected from SSTI in healthcare centers of MS 
surveillance network. 
Strain 
Code 
OX E DA LZD CIP QD SXT P TE FD RD VA CN 
CSAg10A R S S S R R S R S S S S S 
CSC3 R R S S R S S R S R S S S 
CSL3 R R R* S R S S R S S S S S 
CSM4 R R R* S R S S R S S S S S 
CSS4 S S S S R S S R S R S S S 
CSS5 R R R* S R S S R S S S S S 
CSVR8 R R R S R I S R S S S S S 
Abbreviations: R-resistant; I-intermediate-resistant; S-susceptible; OX, oxacillin; E, erythromycin; DA, 
clindamycin; LZD, linezolid; CIP, ciprofloxacin; QD, quinopristin-dalfopristin; SXT, sulfamethoxazole-
trimethoprim; P, penicillin; TE, tetracycline; FD, fusidic acid; RD, rifampicin; VAN, vancomycin; CN, 
gentamicin. 
*Inducible resistant phenotype.  
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3.2.4 Molecular characterization of S. aureus isolates collected from SSTI from 
patients attending healthcare centers of “Médicos Sentinela” surveillance network 
 
All S. aureus isolates were characterized by PFGE, spa typing, SCCmec typing and 
subtyping. Additionally, MLST was performed for all the MRSA isolates and selected 
MSSA isolates.  
 
3.2.4.1 Molecular characterization of MRSA isolates 
 
The MRSA isolates belonged to three different clones: the ST22-IVh (EMRSA-15 
clone), the ST5-IVc (Pediatric clone) and the ST105-II (New York/Japan clone related). 
Interestingly, all these three clones have also been described associated to the hospital 
setting (HSM collection) previously in this master thesis (see Table 9). 
The majority of MRSA isolates (n=4) belonged to CC22, being characterized by PFGE 
type MD, SCCmec type IVh, spa types t032 and 2357 and were assigned to ST22.  
The remaining MRSA isolates (n=3) belonged to CC5 and were characterized by PFGE 
MK. Two of these isolates were characterized by SCCmec type IVc, spa type t535 and 
belonged to ST5. The other isolate was characterized by SCCmec type II, spa type t002 
and belonged to ST105. 
 
3.2.4.2 Molecular characterization of MSSA isolates 
 
Regarding the MSSA isolates, the genetic diversity presented was higher than among 
MRSA isolates. The ST assignments in MSSA isolates was performed based on spa 
typing data, SpaServer database information (http://spaserver.ridom.de) and published 
literature. For the cases in which this association could not be established, or raised 
some doubts, MLST was performed. A total of 13 STs, distributed into ten different CC, 
were identified among the 33 MSSA isolates from the community setting (see Figure 9 
and Table 10). 
 
The most prevalent clonal complex in MSSA was CC5 comprising nine isolates and 
representing 27% of the collection. Six isolates (18%) could be associated to ST5 and 
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were characterized PFGE type MK, spa type t010 or t535. Three isolates (9%) could be 
associated to ST72 and were characterized by PFGE type MG and spa type t148. 
The second most prevalent clonal complex, representing 15% of the MSSA collection, 
was CC15 and comprised five isolates; three isolates (9%) were characterized by PFGE 
type MI, spa type t127 and ST1; one isolate (3%) was characterized by PFGE type MM, 
spa type t9124 and ST15; and one isolate (3%) was characterized by PFGE type MH, 
spa type t189 and ST188. 
 
The remaining 19 MSSA isolates belonged to eight minor clonal complexes: 
- Three isolates probably belonging to CC30 and representing 9% of the MSSA 
collection were characterized by PFGE type ME, spa type t012 or t1988 and could be 
associated to ST30.  
- Three other isolates (9% of the MSSA collection) belonged to CC45 and were 
characterized by PFGE type MB, spa type t576 or t1646 and could be associated to 
ST45. 
- The CC8 represented 9% of the MSSA collection and comprised three isolates that 
could be associated to ST8. Two isolates represented the PFGE type ML and were 
characterized by spa type t008. The other isolate was also characterized by spa type 
t008 but belonged to PFGE type MI. 
- Three isolates belonging to CC7 and representing 9% of the MSSA collection were 
characterized by PFGE type MI, spa type t091 and could be associated to ST7. 
- Two isolates representing 6% of the MSSA collection were associated to CC49 and 
were characterized by PFGE type MC, spa type t4049 and ST49. 
- The remaining clonal complexes were represented by single isolates, representing each 
of these single isolates 3% of the collection. One isolate belonged to CC22 and was 
characterized by PFGE type MD, spa type t790 and was associated to ST22; one isolate 
probably belonged to CC20, being characterized by PFGE type MJ, spa type t164 and 
could be associated to ST20. The other isolate, belonging to CC398, could not be 
characterized by PFGE since no macro restriction profile could be obtained with SmaI 
enzyme. Such trait is characteristic of the ST398 genetic background. The 
characterization of this isolate revealed that it was spa type t4389 and MLST confirmed 
the ST398 assignment. 
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Finally, two isolates could not be associated to a specific clonal background. One isolate 
represented the PFGE type MF and was characterized by spa type t4592. The other 
isolate belonged to PFGE type MG and was characterized by spa type t870. 
 
 
Figure 9 – MSSA population structure from isolates collected from SSTIs from patients attending the 
healthcare centers of MS surveillance network based on MLST and PFGE type. Legend: ST ND - 
Sequence type not determined. 
 
Of note, although PFGE type MI grouped three different genetic backgrounds (CC7, 
CC8 and CC15), if a more restrictive analysis of PFGE type was considered (increasing 
the similarity between isolates) this would allow the splitting of such PFGE type in 
agreement to the remaining molecular characterization. 
 
When the BURP algorithm was applied to the spa data obtained for both MRSA and 
MSSA, three spa-CC were obtained, while the remaining were considered as singletons. 
One cluster, spa-CC 032 comprised the spa types t032, t790 and t2357, being t032 the 
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group founder. Two additional spa-CC, one grouping spa types t002 and t010 and the 
other grouping spa types t012 and 1988, were identified, however in none of the cases a 
group founder was assigned. The remaining spa types (t008, t091, t127, t148, t164, 
t189, t576, t1646, t4049, t4389, t4592 and t9124) were considered singletons, while spa 
types t535 and t870 were excluded from analysis for being shorter than 5 repeats (see 
Figure 9). The result from BURP reinforces the associations constructed for the clonal 
assignment. 
 
Figure 10 – BURP analysis of spa data obtained from isolates collected from SSTIs from patients 
attending healthcare centers of MS surveillance network. spa types are represented by dots and the related 
spa types are linked by a line. The shade of the line varies according to the evolutionary cost between the 
spa types, where a darker shade represents a lower evolutionary cost. The ancestor of spa-CC cluster is 
represented in blue. 
 
Interestingly, when comparing the MRSA and MSSA population structures, it could be 
observed that some clonal backgrounds were shared between the two populations such 
as ST5 and ST22. Moreover, we observed that MSSA and MRSA isolates belonging to 
these STs, additionally, had the same (ST5-t535) or related spa types (ST5-t002/t010; 
ST22-t032/t790). 
 
Additionally, all forty S. aureus isolates from “Médicos Sentinela” study collection 
were screened by PCR for the presence of Panton Valentine Leukocidin and ACME but 
none of the isolates carried the genes encoding these virulence determinants. 
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The main characteristics of S. aureus isolates from “Médicos Sentinela” collection are 
summarized in Table 9 and Table 10. 
Table 9 – Molecular characterization of MRSA isolates from SSTIs collected from patients attending 
healthcare centers of MS surveillance network. 
CC (%) ST PFGE type, no. isolates spa type SCCmec PVL ACME 
22 (57%) 22 MD, 4 t032/ t2357 IVh - - 
5 (43%) 
5 MK, 2 t535 IVc - - 
105 MK, 1 t002 II - - 
 
Table 10 – Molecular characterization of MSSA isolates from SSTIs collected from patients attending 
healthcare centers of MS surveillance network. 
CC, (%) ST 
PFGE type,  
no. isolates 
spa type SCCmec PVL ACME 
5, (27%) 
ST5 MK, 6 t010/t535 - - - 
ST72
 a
 MG, 3 t148 - - - 
15, (15%) 
ST1
 a
 MI, 3 t127 - - - 
ST15 MM, 1 t9124 - - - 
ST188
 a
 MH, 1 t189 - - - 
30, (9%) ST30 
a
 ME, 3 t012/t1988 - - - 
45 (9%) ST45 MB, 3 t576/t1646 - - - 
8 (9%) ST8 
a
 
ML, 2 
t008 - - - 
MI, 1 
7 (9%) ST7 
a
 MI, 3 t091 - - - 
49 (6%) ST49 MC, 2 t4049 - - - 
20 (3%) ST20 
a
 MJ, 1 t164 - - - 
22 (3%) ST22 
a
 MD, 1 t790 - - - 
398 (3%) ST398 NT 
b
, 1 t4389 - - - 
n.d (3%) n.d MF, 1 t4592 - - - 
n.d (3%) n.d MG, 1 t870 - - - 
a
 clonal backgrounds were inferred based on the SpaSever (http://spaserver.ridom.de) and published 
literature [specific case of ST20 and ST72 (24, 179)]. 
b 
couldn’t be restricted by SmaI. 
n.d - not determined; (-) absent. 
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Chapter 4. Discussion and Conclusions 
 
In accordance with the European Antimicrobial Resistance Surveillance Network 
(EARS-Net) report of 2010, Portugal is the European country with the highest MRSA 
prevalence in nosocomial invasive infection, reaching 52.2% (57). However no national 
strategies for MRSA surveillance and control have been successfully defined and or 
applied. However, previous national surveillance studies wherein single hospitals were 
analyzed, have allowed the description of the evolution of MRSA in different 
Portuguese hospitals in the last two decades. According to these studies MRSA clonal 
population suffered several epidemiological changes during time. Still, the factors 
driving clonal replacement are not understood.  
 
Although isolated episodes of infections caused by CA-MRSA in Portugal were already 
reported (35, 133), these reports have been sporadic and it is not known to what extent 
are CA-MRSA disseminated and causing disease in the community in Portugal. 
Moreover the impact of the emergence of CA-MRSA in the epidemiology of MRSA in 
Portugal was never assessed. 
 
In this study we described how and why MRSA clones have evolved in a Central 
Portuguese Hospital in Lisbon within a 17-year period. Moreover, we determined for 
the first time, the frequency and clonal nature of CA-MRSA causing skin and soft tissue 
infection at a national level. The comparison of hospital and community MRSA 
population structures in equivalent time periods revealed that the spillover of MRSA 
from the hospital, rather than the occurrence of CA-MRSA, was the main cause of SSTI 
in persons attending healthcare centers in Portugal. 
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4.1 Massive clonal replacement and diversification in Hospital de Santa 
Maria between 1993 and 2010 
 
MRSA has been endemic in Hospital de Santa Maria since the mid-1980s, with an 
MRSA prevalence of 30% in 1993 (38). In the following years the MRSA prevalence 
stepped up to reach 49% in 2010, which represents an increase of more than 60%. In 
order to try to understand the reasons behind this great increase, two collections from 
HSM recovered in 1993 and 2010 were characterized and compared. 
 
We found that all MRSA isolates collected in 1993 from infection belonged to two 
major clones: the Iberian clone (ST247-I), accounting for 72% of the MRSA isolates, 
and the Portuguese clone (ST239-IIIvariant) accounting for the remaining 28%, both 
belonging to clonal complex 8. This scenario is in agreement with previous reports, 
where the Portuguese clone was described to be the dominant clone until 1991, being 
later replaced by the Iberian clone that dominated between 1992 and 1998 in Portuguese 
hospitals (7, 163, 164). 
 
The analysis of this same collection by PFGE years before (38) identified a total of 24 
PFGE types, what clearly contrasts with the three different PFGE types identified in this 
study. Although the technique used in both studies was the same, the analysis was 
performed in totally different manners. While in the study published before the analysis 
of macro restriction band patterns was done visually and the Tenover criteria were used 
to define a PFGE type; in the study performed here the analysis was assisted by an 
automatic analysis software and the PFGE type was defined by a cut-off of similarity 
(58). Nonetheless we also could identify several different PFGE subtypes within each 
PFGE like was previously described.  
Combining PFGE with, two additional techniques, Cla-mecA and Cla-Tn554 
polymorphisms, methods assessing the variability in the vicinity of mecA and Tn554, 
the authors were able to further discriminate this collection into 26 different clonal 
types. The main conclusion of this previous study was that there were an unusually high 
number of different S. aureus clones in Hospital de Santa Maria. The conclusions drawn 
by our study, wherein completely different methodologies were used (MLST, spa 
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typing, SCCmec typing) differed sharply from this. We found that only two different 
clonal types were present, as defined by ST-SCCmec combinations, but that could be 
further discriminated taking into consideration the results of PFGE type/subtype and 
spa type. The discrepancy of results obtained between the two characterizations can be 
explained by the differences in the typing methods used, namely the evolutionary time 
clocks of the targets analyzed and their discriminatory power, but also the tools used for 
analysis, in the case of PFGE, and the criteria used to define a clone. 
 
In contrast to 1993, MRSA isolates collected from infection in 2010 belonged in its 
great majority (71%) to ST22-IVh, characteristic of the pandemic clone EMRSA-15, 
which belongs to CC22 and to three other clones (ST105-II, ST125-IVc, ST5-IVc) 
belonging to CC5 (22%). Additionally, four clones belonging to CC8, CC30 and CC15 
were also found. The overwhelming dominance of EMRSA-15 in Hospital de Santa 
Maria is in accordance with previous studies, in which ST22 has been described as the 
most prevalent clone nowadays in Portuguese hospitals (4, 11). In these same studies, 
the New York/Japan clone had been suggested as the most probable next emergent 
MRSA clone in the nosocomial setting in Portugal. However, in this study we observed 
that two clones (ST105-II and ST125), belonging to CC5, other than the New 
York/Japan, might be candidates to become new emerging clone. These clones differing 
from ST5 by one point mutation on yqil locus have already been described as major 
clones in the hospital in Switzerland (20) and Spain (13, 150, 151, 194) and as minor 
clones in Brazil (25), the USA (33) and Norway (61). However, as far as we are 
concerned, this is the first time that ST105-II and ST125-IVc are reported in a 
Portuguese hospital. 
 
Since these clones accounted for 22% of the MRSA isolates in 2010, and have already 
proven to be capable of disseminating in the hospital and becoming dominant, it can be 
speculated that EMRSA-15 has started to be replaced or will be replaced by ST105-II 
and ST125-IVc in the near future. 
 
Although there is no information on the MRSA population in HSM between 1994 and 
2009, it could be assumed that HSM followed the national trend over the years, where 
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the multiresistant Brazilian clone, after its introduction in 1994-1995, rapidly 
disseminated and became dominant nationwide between 1998 and 2000 (7, 145). This 
scenario is well demonstrated in a previous study in Hospital Geral de Santo António in 
Oporto (10) where in the Iberian clone, the dominant clone in this hospital in the period 
between 1992 and 1993, was replaced by the Brazilian clone in the period of 1996-
2000. 
Most interestingly, three isolates related to the Brazilian clone, new SLV of ST239-III 
(ST2246-III), were found in the MRSA HSM collection from 2010 analyzed in this 
study. These could be remnants of the previous clonal wave where the Brazilian clone 
was prevalent or could have been imported from Asian or Middle East countries, 
wherein the Brazilian clone is presently the most prevalent clone. 
 
The comparison of the results obtained for the population structure of MRSA collected 
in 1993 and 2010, revealed that there was an increase in the genetic diversity of MRSA 
clonal types. More importantly, a major shift in the clonal population of MRSA 
occurred within the 17-year interval. In fact, no common PFGE types, spa types or STs 
were found between the two study periods. The only CC that prevailed between the two 
study periods was CC8, but associated to completely distinct clones. 
 
During its recent history, specifically during the period analyzed in this study (1993-
2010), Hospital de Santa Maria has suffered several structural changes such as the 
integration into a Hospital center constituted also by other hospitals, that could have 
impacted the overall population structure of microorganisms living in the hospital, 
namely that of MRSA. The observed diversification of clones and increase in MRSA 
frequency may derive from the fact that at this moment the hospital embraces a much 
more diversified and larger human population.  
The clonal replacement that occurred in the hospital within the 17-year study period is a 
characteristic of MRSA epidemiology and has occurred in the past in Portugal and all 
over the world. In this case, a multidrug resistant clone like the Portuguese/Brazilian 
clones was replaced by a clone that contains much less antibiotic resistant traits, but that 
appears to have an enhanced capacity to survive in multiple environments, such as the 
hospital (4, 8, 9, 11, 36, 87, 120), the community (126, 138) and even environmental 
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surfaces (170). Although the reasons lying behind the fade of one clone and the 
emergence of the other are not completely explained, it is believed that the newly 
introduced clone has a higher fitness than the established one. The fact that EMRSA-15 
clone carries few resistant traits, a smaller SCCmec type and an increased capacity to 
form biofilm (172) may have conferred to this particular clone a higher mobility, 
growth rate and persistence capacity, what could explain its success and fitness. To 
further prove this hypothesis we are planning to perform fitness experiments between 
the several clones that were replaced during time in Portugal.  
 
The capacity of EMRSA-15 to survive in different environments may have lead to 
consecutive cycles of introduction and re-introduction of the EMRSA-15 clone in the 
hospital through the community. A phenomenon that did not occur in the past, given the 
inability of the Portuguese and Iberian clones of shuffling between the two 
environments probably due to the carriage of bigger SCCmec types and multidrug 
resistance. This may explain the increase of the MRSA frequency observed in the 
hospital between 1993 and 2010. 
 
4.2 MRSA from SSTI of persons attending health-care centers have hospital 
origin 
 
One of the aims of this master thesis was to investigate the prevalence and clonal 
structure of S. aureus causing SSTIs, one of the most frequent presentations of S. 
aureus infections, especially in the community (41). 
Despite the fact that Portugal has a high incidence of MRSA in the nosocomial setting, 
the frequency of MRSA in the nasopharinx was shown to be extremely low (less than 
0.5%) (160, 179). However, the information about MRSA prevalence in infection in the 
Portuguese community is very scarce. Some studies conducted in Portugal wherein the 
frequency of CA-MRSA in infection was assessed at hospital admission showed that 
MRSA rate could vary between 5 and 8% (35, 178). However until the beginning of this 
study, the frequency of MRSA causing infection in the population attending healthcare 
centers in Portugal had never been evaluated.  
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We identified a MRSA infection rate of 17.5% among SSTI of patients attending 
healthcare centers. However, we cannot disregard the fact that a low number of samples 
were recovered. Moreover, many SSTIs are usually treated by draining without 
collection, what suggests that the MRSA rate could be higher than that obtained in this 
study.  
 
Three out of seven MRSA were isolated from people with at least one risk factor for 
healthcare-associated MRSA and therefore the possibility of having been originated in 
the hospital cannot be discarded. All the MRSA isolates obtained in this study were 
recovered from elderly people, which for their intrinsic condition, have a higher 
probability of having a history of hospitalization and surgery or other risk factors 
associated with a previous contact with healthcare-associated MRSA. This situation is 
in clear contrast with previous studies, where MRSA infections occurring in the 
community in the USA seemed to affect a healthy population with no identifiable risk 
factors, namely children and young people (41, 79, 132). 
 
Interestingly, the seven MRSA isolates recovered in persons attending healthcare 
centers belonged to clones usually associated to the nosocomial setting, such as ST5-
IVc-t535, ST105-II-t002 and ST22-IVh-t032/t2357, irrespective of the fact that risk 
factors for hospital contact were identified or not. Noteworthy, five of these seven 
isolates presented a multidrug resistance profile and were exactly the same as those 
found among MRSA collected from Hospital de Santa Maria in 2010. 
A high rate of HA-MRSA clones (ST22-IVh and ST5-II) causing infection in persons 
attending hospitals with no risk factors for previous hospital contact was previously 
observed in Portugal (178), suggesting the spill over of HA-MRSA isolates into the 
community. Although in our study we could not identify any CA-MRSA isolates 
causing SSTI, isolates belonging to CA-MRSA clones were already described as 
colonizers (ST82-IV, ST72-IV, ST939-IVa and ST931-VI) (179) or infectious agents 
(ST80-IVc, ST8-IVa, ST398-V) (178) in the community in Portugal. 
Overall, the isolation of multidrug resistant nosocomial MRSA in the community 
suggests that these clones might be escaping from hospital into the community and 
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becoming established in this setting. If this is true, we might be in the verge of vast 
public healthcare concern in the near future. 
 
4.3 High epidemicity of MSSA from SSTI of patients attending health-care 
centers  
 
Concerning the methicillin-susceptible S. aureus, the isolates identified among SSTI of 
persons attending healthcare centers presented a higher genetic variability than their 
resistant counterparts. A total of 13 different STs were identified (ST1, 5, 7, 8, 15, 20, 
22, 30, 45, 49, 72, 188 and 398), which included STs previously described in Portugal 
both in colonization and infection (ST1, 5, 8, 15, 20, 22, 30, 45, 72, 188) (3, 35, 70) and 
in several European countries (ST1, 5, 7, 8, 15, 20, 22, 30, 45) (70). However we also 
identified less frequent clones like ST49 that has been mostly associated with wild 
animals (squirrels) and pigs (34, 37, 46), and ST188 and ST398 described both in 
humans and animals (65, 91, 100, 191). The results suggest that MSSA isolates from 
this study, in their majority have high epidemic capacity. Moreover, we observed that 
some of the isolates found among SSTI in persons attending healthcare centers could 
have originated from animals. This might result from the fact that many of the 
healthcare centers analyzed were located in rural areas, where the contact with farm 
animals is privileged. 
 
Interestingly, when we compared the population structures of MSSA and MRSA 
isolates collected from SSTI in healthcare centers, we observed that some MSSA and 
MRSA isolates shared the same or related genetic characteristics. This is the case of 
MRSA and MSSA isolates belonging to ST22 that shared PFGE type MD and had 
related spa types (t790, t032, t2357); and the case of ST5 that shared both PFGE type 
MK and t535. The results suggest that MRSA isolates found in the community probably 
lost SCCmec due to the absence of antibiotic pressure. 
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4.4 MRSA clones: evidence for the weakening of barriers between the 
Hospital and Community  
 
Worldwide, there have been some reports of major nosocomial MRSA clones being 
isolated from the community (126) and, vice-versa, community-associated clones being 
found as cause of nosocomial outbreaks (93, 146, 166). However, this has been 
observed for few specific MRSA clones that seem to be capable of surviving and spread 
in both environments. 
Altogether in our study we found evidence that support that the same type of 
phenomenon is occurring in Portugal, leading to the spread of HA-MRSA clones 
(ST22-IVh-t032/2357, ST105-II-t002 and ST5-IVc-t535) in the community. This might 
result from the high frequencies of MRSA observed inside the hospital in Portugal. 
However, it might also result from intrinsic characteristics of the HA-MRSA clones 
found nowadays in our hospitals that allowed them to spread in the community, like the 
carriage of SCCmec IV and low antimicrobial resistance profile. However, in the 
absence of antibiotic pressure, MRSA in the community probably lose frequently the 
SCCmec giving rise to MSSA with the same genetic background, as was the case of 
MSSA belonging to ST22 and ST5 clones. The role of EMRSA-15 clone in the hospital 
and community both in infection and colonization is well documented (4, 8, 9, 11, 36, 
126, 138). And its capacity of dissemination and invasion can be even enhanced by the 
acquisition of additional virulence factors like ACME and PVL as was already 
described (105, 159, 169). 
 
The vehicles of dissemination of HA-MRSA from the hospital into the community are 
not known. But EMRSA-15 clone was found as a major clone colonizing public buses 
handles in the region of Oporto, accounting for 91% of the isolates (170), what could 
function as important reservoir of this clone for the community. But patients themselves 
and healthcare workers may be also the main means of spreading. 
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Annexes 
 
1. Culture media 
 
Table 1 – Culture media and composition (per Liter). 
Culture media Composition  
Tryptic Soy 
Agar (TSA) 
15g of pancreatic digest of casein; 5g of papaic digest of soybean; 5g 
of sodium chloride and 15g of agar. pH 7.3±0.2. 
Tryptic Soy 
Broth (TSB) 
17g of pancreatic digest of casein; 3g of papaic digest of soybean; 
2.5g of dextrose; 5g of sodium chloride and 2.5g of dipotassium 
phosphate. pH 7.3 ± 0.2. 
Mannitol Salt 
Agar (MSA) 
5g of pancreatic digest of casein; 5g of peptic digest of animal tissue; 
1g of beef extract; 75g of sodium chloride; 10g of D-mannitol; 0.025g 
of phenol red and 15g of agar. pH 7.4 ± 0.2. 
Mueller-Hinton 
II Agar (MH) 
2g of beef extract; 17.5g of acid hydrolysate of casein; 1.5g of starch 
and 17g of agar. pH 7.3 ± 0.1 
 
 
2. Enzymes 
 
Table 2 – Enzymes for cellular lysis and DNA purification. 
Enzyme Composition 
RNase A 10 mg/ml in sterile purified water. Boiled at 100ºC for 15 minutes. 
Conserved at -20ºC in 200 µl aliquots. 
Lisozyme 20 mg/ml in sterile purified water. Conserved at -20ºC in 200 µl 
aliquots. 
Lysostaphin 10 mg/ml in sterile 20mM sodium acetate, pH 4.5. Conserved at -20ºC 
in 200 µl aliquots. 
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3. Buffers and Solutions 
 
Table 3 – Buffers and DNA extraction solutions. 
Solution Preparation of stock solution 
PIV 0.01 mM Tris-HCl pH 8.0; 1 M NaCl 
Tris buffer 10 mM Tris-HCl pH 8.0. 
TE 10X 10mM Tris pH 7.5; 1 mM EDTA pH 8.0. 
TAE 50X 0.5 M Tris; 0.05 M EDTA pH 8.0; 1 M acetic acid. 
TBE 10X 1M Tris; 1 M boric acid; 0.2 M EDTA pH 8.0. Adjust to pH 8.5. 
EC lysis solution 6mM Tris pH 8.0; 1 M NaCl; 100 mM EDTA pH 8.0; 0.2% (w/v) 
sodium deoxycholate; 0.5% (w/v) sodium laurylsarcosine. After 
sterilization, enzymes were added: 50 µg/ml RNase A, 100 µg/ml 
lysosyme and 50 µg/ml lysostaphin. 
ESP solution 0.5 M EDTA pH 9.0; 1% sarcosyl. After sterilization, 1mg/ml of 
proteinase K was added. 
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4. Primers List 
Table 4 – Nucleotide sequences (5’-3’ orientation) of primers used in this study. Target region and expected size of the amplicon is shown, as well the bibliographic 
references where the primers were first described. 
Assay 
Target 
region 
Primers sequence (5’ to 3’) Amplicon Size (bp) Reference 
mecA gene 
detection 
mecA gene 
mecA P4: TCCAGATTACAACTTCACCAGG 
mecA P7: CCACTTCATATCTTGTAACG 
162 (141) 
mec complex 
identification 
mec complex 
A (mecI) 
mI4: CAAGTGAATTGAAACCGCCT 
mI3: CAAAAGGACTGGACTGGAGTCCAAA 
180 (139) 
mec complex 
B (IS1272-
mecA) 
IS5: AACGCCACTCATAACATATGGAA 
mA6:  CATAACTTCCCATTCTGCAGATG 
2000 
(139) 
(88) 
ccr genes 
identification 
ccrAB1 
1: AACCTATATCATCAATCAGTACGT 
c: ATTGCCTTGATAATAGCCITCT 
700 
(139) 
ccrAB2 2: TAAAGGCATCAATGCACAAACACT 1000 
ccrAB3 3: AGCTCAAAAGCAAGCAATAGAAT 1600 
ccrAB4 
ccrAB4 F1: TCATCAATAAGTATGGAACG 
ccrAB4 R1: TTTCTTGCGACTCTCTTGG 
1500 (142) 
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Table 4 – Continuation. 
Assay Target region Primers sequence (5’ to 3’) Amplicon Size (bp) Reference 
SCCmec 
typing 
SCCmec I, J1 
region 
CIF2 F2: TTCGAGTTGCTGATGAAGAAGG 
CIF2 R2: ATTTACCACAAGGACTACCAGC 
495 
(141), 
(122) 
 
SCCmec V, ccr 
complex 
ccrC F2: GTACTCGTTACAATGTTTGG 
ccrC R2: ATAATGGCTTCATGCTTACC 
449 
SCCmec III, J3 
region 
RIF5 F10: TTCTTAAGTACACGCTGAATCG 
RIF5 R13: ATGGAGATGAATTACAAGGG 
414 
SCCmec V, J1 
region 
SCCmec V J1 F: TTCTCCATTCTTGTTCATCC 
SCCmec V J1 R: AGAGACTACTGACTTAAGTGG 
377 
SCCmec I, II, IV 
and VI – J3 region 
dcs F2: CATCCTATGATAGCTTGGTC 
dcs R1: CTAAATCATAGCCATGACCG 
342 
SCCmec II and IV, 
ccr complex 
ccrB2 F2: AGTTTCTCAGAATTCGAACG 
ccrB2 R2: CCGATATAGAAWGGGTTAGC 
311 
SCCmec II, J1 
region 
kdp F1: AATCATCTGCCATTGGTGATGC 
kdp R1: CGAATGAAGTGAAAGAAAGTGG 
284 
SCCmec III, J1 
region 
SCCmec III J1 F: CATTTGTGAAACACAGTACG 
SCCmec III J1 R: GTTATTGAGACTCCTAAAGC 
243 
SCCmec II and III, 
mec complex 
mecI P2: ATCAAGACTTGCATTCAGGC 
mecI P3: GCGGTTTCAATTCACTTGTC 
209 
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Table 4 – Continuation. 
Assay Target region Primers sequence (5’ to 3’) Amplicon Size (bp) Reference 
SCCmec 
typing 
mecA gene 
mecA P4: TCCAGATTACAACTTCACCAGG 
mecA P7: CCACTTCATATCTTGTAACG 
162 (141), (122) 
SCCmec VI 
subtyping 
J1 region 
ccrB2 F:  CGAACGTAATAACATTGTCG 
ccrB2 R: TTGGCWATTTTACGATAGCC 
203 
(122), (121) 
J1IVa F: ATAAGAGATCGAACAGAAGC 
J1IVa R: TGAAGAAATCATGCCTATCG 
278 
J1IVb F: TTGCTCATTTCAGTCTTACC 
J1Ivb R: TTACTTCAGCTGCATTAAGC 
336 
J1Ivc F: CCATTGCAAATTTCTCTTCC 
J1Ivc R: ATAGATTCTACTGCAAGTCC 
483 
J1Ivd F: TCTCGACTGTTTGCAATAGG 
J1Ivd R: CAATCATCTAGTTGGATACG 
575 
J1Ivg F: TGATAGTCAAAGTATGGTGG 
J1Ivg R: GAATAATGCAAAGTGGAACG 
792 
J1Ivh F: TTCCTCGTTTTTTCTGAACG 
J1Ivh R: CAAACACTGATATTGTGTCG 
663 
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Table 4 – Continuation. 
Assay Target region Primers sequence (5’ to 3’) Amplicon Size (bp) Reference 
spa typing spa gene 
1113 F: TAAAGACGATCCTTCGGTGAGC 
1514 R: CAGCAGTAGTGCCGTTTGCTT 
variable 
(2) 
spa F2: GAACAACGTAACGGCTTCATCC 
spa R1: CAGCAGTAGTGCCGTTTGC 
(97, 140, 167) 
MLST 
arcC 
arcC F2: CCTTTATTTGATTCACCAGCG 
arcC R1: AGGTATCTGCTTCAATCAGCG 
456 
(39, 55) 
aroE 
aroE F1: ATCGGAAATCCTATTTCACATTC 
aroE R1: GGTGTTGTATTAATAACGATATC 
456 
glpF 
glpF F1: CTAGGAACTGCAATCTTAATCC 
glpF R1: TGGTAAAATCGCATGTCCAATTC 
465 
gmk 
gmk F1: ATCGTTTTATCGGGACCATC 
gmk R1: TCATTAACTACAACGTAATCGTA 
429 
pta 
pta F1: GTTAAAATCGTATTACCTGAAGG 
pta R1: GACCCTTTTGTTGAAAAGCTTAA 
474 
tpi 
tpi F1: TCGTTCATTCTGAACGTCGTGAA 
tpi R1: TTTGCACCTTCTAACAATTGTAC 
402 
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Table 4 – Continuation. 
Assay Target region Primers sequence (5’ to 3’) Amplicon Size (bp) Reference 
MLST yqiL 
yqiL F1: CAGCATACAGGACACCTATTGGC 
yqiL R1: CGTTGAGGAATCGATACTGGAAC 
516 (39, 55) 
ACME 
arcA 
arcA F: GAGCCAGAAGTACGCGAG 
arcA R: CACGTAACTTGCTAGAACGAG 
671 (47) 
opp3 
AIPS.45: GCAAATCTGTAAATGGTCTGTTC 
AIPS.46: GAAGATTGGCAGCACAAAGTG 
1183 (50) 
PVL 
lukS-PV and lukF-
PV genes 
PVL 1: ATCATTAGGTAAAATGTCTGGACATGATCCA 
PVL 2: GCATCAASTGTATTGGATAGCAAAAGC 
433 (104) 
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5. Questionnaire addressed to patients attending healthcare centers in Portugal, 
presenting skin and soft tissue infections.  
 
Table 5 – Questions included in the questionnaire for assessment of risk factors for hospital contact 
addressed to patients attending healthcare centers in Portugal, presenting skin and soft tissue infections. 
 Questions included in the questionnaire for risk factors assessment 
1 Was hospitalized in the last 12 months? 
2 Has or had been in regular contact with Geriatric Day Centers? 
3 Has been infected or colonized by MRSA in the last 12 months? 
4 Subjected to any surgery in the last 12 months? 
5 Subjected to dialysis or permanent catheter in the last 12 months? 
6.a Has taken any antibiotic in the last 12 months? 
6.b If yes, please specify the antibiotic. 
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Table 6 – List of S. aureus isolates collected from skin and soft tissue infections of patients attending healthcare centers and respective information from the 
questionnaires. Legend: M - Male; F - Female; NI - no information; N - No; Y - Yes. 
Strain Code Age (years) Sex 
Sample 
source 
Was 
hospitalized in 
the last 12 
months? 
Has or had been in 
regular contact 
with Geriatric Day 
Centers? 
Has been infected 
or colonized by 
MRSA in the last 
12 months? 
Subjected to any 
surgery in the 
last 12 months? 
Subjected to dialysis 
or permanent 
catheter in the last 
12 months? 
Has taken any 
antibiotic in the 
last 12 months? 
CSAg1 67 M NI N N NI N N Y 
CSAg2 80 M Ulcer N N NI N N Y 
CSAg3 62 F NI N N NI N N Y 
CSAg4 55 M Ulcer N N N N N N 
CSAg5 64 M Ulcer N Y N N N N 
CSAg6 66 F NI N N NI N N Y 
CSAg9 93 F NI N N N N N N 
CSAg10A 68 M NI Y N N Y N NI 
CSAv1 37 M Fistula Y N NI Y N Y 
CSAv2 56 F Ulcer N N Y N N Y 
CSAv3 77 M Ulcer N N Y N N Y 
CSAv4A 68 F Ulcer Y N NI N N Y 
CSBa1A 93 M Celullitis N Y Y N N N 
CSBa4G 60 F NI N N N N N Y 
CSBa6 62 M Celullitis N N N N N Y 
CSBa8 55 F Celullitis N N N N N N 
CSBa10A 16 F Celullitis Y N N Y N N 
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Table 6 – Continuation. 
Strain Code Age (years) Sex 
Sample 
source 
Was 
hospitalized in 
the last 12 
months? 
Has or had been in 
regular contact 
with Geriatric Day 
Centers? 
Has been infected 
or colonized by 
MRSA in the last 
12 months? 
Subjected to any 
surgery in the 
last 12 months? 
Subjected to dialysis 
or permanent 
catheter in the last 
12 months? 
Has taken any 
antibiotic in the 
last 12 months? 
CSBa12 78 M 
Infected 
wound 
N N N N N Y 
CSBa14 81 F NI N N N N N Y 
CSC1 77 M 
Chronic 
wound 
N N NI N N Y 
CSC2 57 M Ulcer N N NI N N Y 
CSC3 87 F Ulcer N N N N N Y 
CSC4 88 M Ulcer N N NI NI N Y 
CSC5 66 F Celullitis N N NI N N Y 
CSL1A 82 F NI N N N N N Y 
CSL2 77 M Ulcer N N NI N N Y 
CSL3 82 M NI N N NI N N Y 
CSL4 61 M Ulcer Y Y NI Y NI Y 
CSM1 57 M NI N N NI N N Y 
CSM2 71 F NI Y N NI Y Y Y 
CSM4 90 F NI N Y NI N N Y 
CSS1 77 M NI Y N NI N N Y 
CSS4 72 M NI N N NI N N Y 
CSS5 74 M NI N N NI N N Y 
CSS6 64 M NI Y N N NI N Y 
CSVR2 46 M Fasciitis N NI NI N N Y 
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Table 6 – Continuation. 
Strain Code Age (years) Sex 
Sample 
source 
Was 
hospitalized in 
the last 12 
months? 
Has or had been in 
regular contact 
with Geriatric Day 
Centers? 
Has been infected 
or colonized by 
MRSA in the last 
12 months? 
Subjected to any 
surgery in the 
last 12 months? 
Subjected to dialysis 
or permanent 
catheter in the last 
12 months? 
Has taken any 
antibiotic in the 
last 12 months? 
CSVR3A 53 M Fasciitis N N NI N N Y 
CSVR4 71 M 
Abcess, 
ulcer, 
fasciitis 
Y N N Y N Y 
CSVR5 38 M Abcess N N Y N N Y 
CSVR8 81 F Celullitis Y Y NI N N Y 
 
